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ABSTRACT 
 
 
SELECTIVE LESION OF CHOLINERGIC NEURONS OF THE SEPTAL  
 
HIPPOCAMPAL TRACT: MEMORY AND LEARNING 
 
 
 
 
 
 
 
By 
 
Nicholas Fitz 
 
May 2009 
 
 
 
Dissertation supervised by David A. Johnson Ph.D. 
 
It is hypothesized that the loss of cholinergic function in the medial septum (MS), 
observed early in many forms of dementia, contributes to memory losses characterized in 
these diseases.  The studies of this dissertation examined whether the selective loss of 
cholinergic neurons in the MS impairs acquisition of a delayed matching-to-position 
(DMP) spatial memory task.  The results suggest a significant contribution of MS 
cholinergic neurons in acquisition of the DMP task.  Specifically, 192 IgG-saporin SAP 
lesioned rats acquired the task at a slower rate and required more days to reach criterion.  
The results also suggest that male rats typically adopt a consistent turning strategy early 
in the training process, which is independent of extra-maze cues.  For animals to reach 
criterion, an alternative learning strategy was adopted; one dependent on extra-maze 
cues.  Cholinergic lesion of the MS resulted in a greater reliance on a consistent turning 
strategy, which accounted for the slower rate of acquisition of the DMP task.   
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 Steroid sulfatase inhibitors increase whole brain DHEAS levels, enhance ACh 
release in the hippocampus, and enhance memory.  The present study also investigated 
the cognitive effects of sulfatase inhibition in SAP lesioned animals.  Steroid sulfatase 
inhibition further impaired acquisition of the DMP task in SAP lesioned rats while having 
no effect on cholinergically intact animals.  Since DHEAS displayed memory enhancing 
properties in rodents, we also investigated the effects of DHEAS administration on MS 
SAP lesioned animals.  DHEAS treatment had no significant effect on the acquisition of 
the DMP task in the SAP treated or control animals.  
 The final study of this dissertation examined the effect of arousal on DMP 
performance in SAP lesion of the medial septum.   Arousal, induced by the IP injection of 
saline, decreased the number of days SAP lesioned rats needed to reach criterion and also 
improved the rate of acquisition.  The results suggest that a mild aversive stimulus can 
attenuate cognitive deficits caused by MS cholinergic lesions.   
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I.  INTRODUCTION 
 
 
A.  Literature Review 
1.  Dementia: 
 Dementia is a syndrome characterized by neuropsychological, neuropsychiatric, 
and neurologic manifestations.  Particularly affected functions include memory, attention, 
language, and problem solving.  Symptoms of dementia can be reversible or irreversible.  
Reversible causes of dementia include hypothyroidism, Vitamin A, B1, or B12 deficiency, 
tumors, normal pressure hydrocephalus, or syphilis; but these only account for less than 
10% of clinical cases.  Irreversible dementias include Alzheimer’s disease, vascular 
dementia, alcohol induced persisting dementia, and frontotemporal lobar degeneration.  
There is an estimated 24 million people worldwide with clinical symptoms of dementia, 
and this number is projected to increase to 81 million by 2040 (1).   
Alzheimer’s disease (AD) is the most common type of dementia in the elderly, 
affecting almost half of all patients with dementia.  More that 5 million Americans are 
estimated to have AD and it is projected that 14.3 million Americans will develop the 
disease by 2050; a 350% increase from 2000 (2).  Among patients 65 years of age, 2-3% 
display symptoms of the disease, while nearly 50% of patients 85 years of age or older 
have symptoms of AD and an even greater number display some of the pathological 
hallmarks of the disease without presenting the symptoms.  Statistics show that for every 
five years a person lives past the age of 65, the probability of developing the disease 
doubles (3).  As global life expectancy rises, patients over the age of 85 are the fastest 
growing segment of the AD population.  Therefore, advanced aging is a primary risk 
factor for the disease.  Clinicians who diagnose and treat patients with AD generally 
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recognize that the prevalence of AD is higher in women (3).  Possibly due to the relative 
lack of a protective factor, such as the estrogen deficiency of postmenopausal women, 
which may increase the vulnerability to AD pathology. 
 For most patients diagnosed with the disease, increased impairments in learning 
and short-term memory will lead to a diagnosis of dementia, while small populations may 
also display signs of language and visual-spatial difficulties (4).  Memory problems do 
not affect all memory capacities equally, with older memories of the patient’s life, facts 
learned, and implicit memory commonly spared (5-6).  These initial symptoms progress 
from simple forgetfulness and the inability to navigate simple tasks, to more persistent 
losses of short-term memory and difficulty navigating through familiar areas, such as 
one’s own home.  As the disease progresses to the moderate stage of memory loss, 
patients fail to recognize familiar objects and persons (4).  During this stage of the 
disease, patients may also show changes in behavior, such as violent outbursts or 
excessive passivity without prior history of such behaviors.   In late stages of the disease, 
patients lose the ability to perform even simple tasks independently.  Patients become 
incontinent of bladder and bowel, and/or lose the ability to walk or eat without assistance.  
In late stages of AD, language becomes disorganized and then lost altogether.  
Eventually, the ability to swallow food or drink is lost, ultimately leading to death (4).  In 
2004, with 65,829 deaths, AD was the seventh leading cause of death in the United States 
(7).  The mean duration of the disease is 8.5 years between onset of the clinical symptoms 
and death.  At a cost of over $100 billion per year, AD is the third most costly disease in 
the United States, after heart disease and cancer.  Direct and indirect costs for long term 
care for an Alzheimer’s patient averages $77,500 per year (8).              
2 
 
 Regions associated with higher brain function, particularly the neocortex and 
hippocampus, are most affected by the pathology of AD.  Pathological changes include 
extracellular deposits of β-amyloid, a proteolytic byproduct of the transmembrane protein 
amyloid precursor protein.  Although β-amyloid monomers are soluble and harmless, 
they undergo a conformational change at high concentrations to form a β-sheet rich 
tertiary structure that aggregates to form amyloid fibrils.  These amyloid fibrils are 
deposited extracellularly, forming dense senile plaques.  Another pathological 
characteristic of AD is abnormal aggregation of tau protein, a microtubule associated 
protein expressed in neurons that normally acts to stabilize microtubules in the 
cytoskeleton.  Like most microtubule-associated proteins, tau is normally regulated by 
phosphorylation.  However in AD patients, hyperphosphorylated tau accumulates as 
paired helical filaments that form intracellular neurofibrillary tangles and dystrophic 
neurons associated with amyloid plaques (9).  There is also a significant loss of neuronal 
synapses and pyramidal neurons within the brain regions associated with higher cognitive 
function.  The cholinergic basal forebrain neurons are one of the most sensitive targets of 
degenerative processes occurring in patients with AD (10-11).              
 Three major competing hypotheses exist to explain the cause of Alzheimer’s 
disease.  The cholinergic hypothesis of AD proposes that degeneration of cholinergic 
neurons in the basal forebrain and the associated loss of cholinergic neurotransmission in 
the cerebral cortex and hippocampus contributes significantly to the deterioration of 
cognitive function seen in AD patients (12).  In support of this hypothesis, postmortem 
AD brains are characterized by neuronal loss and neurofibrillary tangle formation in 
regions of the neocortex and hippocampus, primarily affecting pyramidal neurons and 
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their synapses (13-14).  Furthermore, neurotransmitter specific projections to the cortex 
and hippocampus are affected by neurodegenerative processes, including cholinergic 
nucleus basalis and medial septum projections (11).  For example, AD affected brains 
have an almost 80% reduction in cholinergic neurons of the nucleus basalis compared to 
age-matched control brains.  Biochemical examination of biopsy tissues from patients 
with AD 3.5 years following the onset of symptoms indicate selective cholinergic 
pathologies occur early in the course of the disease (15).  Specifically, presynaptic 
markers of cholinergic activity are greatly reduced.  Reduction of choline 
acetyltransferase (ChAT) activity and acetylcholine (ACh) synthesis were strongly 
correlated with the degree of cognitive impairment in AD patients (15-18).  Subsequent 
findings of reduced choline high-affinity uptake, impaired ACh release, deficits in 
expression of nicotinic and muscaric cholinergic receptors, and loss of cholinergic soma 
from the nucleus basalis confirmed a substantial presynaptic deficit (reviewed in 19).  
Cholinergic effects have also been proposed to initiate large-scale β-amyloid aggregation 
leading to generalized inflammation (20).  In further support of the cholinergic 
hypothesis for AD, anticholinergic drugs impair learning and memory in a way that was 
similar to that observed with AD (21).  Currently, despite these findings, the cholinergic 
hypothesis is not widely accepted.  Even if the disruption of the cholinergic system is not 
the first stage of the pathogenesis of AD, it is still a major event that is involved in the 
loss of cognitive function, a key hallmark of the disease. 
 The other hypotheses for the pathogenesis of AD focus on the effects of the 
misfolded and aggregated proteins β-amyloid and tau.  One hypothesis states that tau 
hyperphosphorylation initiates the disease cascade, while another hypothesis states that β-
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amyloid deposits are the initiating factor.  The tau hypothesis is supported by the 
observation that the deposition of amyloid plaques do not correlate well with the neuronal 
loss observed in AD (22).    The cloning of the gene encoding the β-amyloid precursor 
protein and its localization to chromosome 21, coupled with the earlier observation that 
Down’s syndrome (Trisomy 21) mimics the neuropathology of AD, lead to the 
hypothesis that β-amyloid accumulation is the primary event in AD pathogenesis.  The 
formulation of the amyloid hypothesis points to the cytotoxicity of mature aggregated 
amyloid fibrils, which are thought to disrupt calcium homeostasis and thus induce 
apoptosis (23-24).   
 There is currently no cure for AD and the medications currently available offer 
only small symptomatic benefit for some patients, but do not slow disease progression.   
Approaches for treating AD disease have focused on augmenting cholinergic function, 
since decreased central cholinergic activity appears to be an important component of the 
pathology of memory and attentional deficits associated with AD.  Drug therapies can 
enhance cholinergic function through several different mechanisms.  
Acetylcholinesterase (AChE) inhibitors (tacrine, donepezil, galantamine, rivastigmine) 
enhance cholinergic function by inhibiting the hydrolysis of ACh and therefore, heighten 
the concentration of ACh at the post-synaptic receptor sites.  Unfortunately, AChE 
inhibitors, aside from being marginally effective, are also limited by a lack of specificity.  
Moreover, they do not alter the course of the underlying disease process.         
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2. Learning and Memory 
 Learning is the cognitive process of acquiring skills, knowledge, and 
understanding from study, instruction, or experience that help guide long term behaviors.  
During animal behavioral testing, learning occurs when a new response becomes 
associated with a particular stimulus is termed associative learning.  Associative learning 
occurs through classical and instrumental conditioning.  The typical procedure for 
inducing classical conditioning involves presentation of light or sound followed by 
administration of food.  During classical conditioning animals learn to associate the light 
with food.  Habituation is the waning of an animal’s behavioral response to a stimulus.  
Habituation is usually considered a form of learning which involves the elimination of 
behaviors that are not needed by the animal.  Habituation is separated from most other 
forms of decreased response on the basis that the change in behavior is permanent; 
habituated animals do not resume earlier reaction to the stimulus after a period of non-
stimulus.  Learning would be extremely inefficient if humans had to rely completely on 
classical and instrumental conditioning.  Unlike in animals, humans can acquire 
information through cognitive learning.  Cognitive learning is defined as the acquisition 
of knowledge and skill by mental processes, observation, instruction, and imitation of 
behavior.  In cognitive learning, the individual learns by listening, watching, touching, 
reading, or experiencing. 
 Memory is defined as the mental faculty of retaining and recalling past 
experiences (25).  From an informational processing standpoint there are three stages in 
memory formation: encoding, storage, and retrieval.  Encoding is the processing of 
sensory input into memory.  During memory encoding, information is processed about 
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space, time, and frequency.  Storage is the organization of the encoded information that is 
retained in sensory, short-term, or long-term memory.  Retrieval of memory involves the 
recall of stored information and can be classified into three different categories:  free 
recall (no clues given to assist retrieval), serial recall (items recalled in a particular order), 
and cued recall (clues given to assist retrieval) (26).  During retrieval of memories 
neurons are activated and fired in the same pattern as during the encoding process.   
 Memory can be generically classified on the bases of the duration of memory 
retention (26).  In this classification system memory can be divided into: sensory 
memory, short-term memory, and long-term memory.  Sensory memory is the retention 
of impressions of sensory information after the original stimulus has ceased.  It refers to 
items detected by sensory receptors which are retained temporarily in the sensory 
inventory.  Sensory inventory has a large capacity for unprocessed information but is 
only able to hold accurate images of sensory information momentarily.  Without 
rehearsal, sensory memory typically lasts less than 1 sec and no more than 2 sec.  Visual 
sensory memory is commonly called iconic memory, while auditory sensory memory is 
referred to as echoic memory.  Typically tests of iconic memory involve exposing 
subjects to a grid of three rows of four letters for a brief period.  Participants must then 
recall as many letters as they can and also the row in which the letters were found.   
 Short-term memory is defined as the capacity to hold a small amount of 
information in an active, readily available state.  Short-term memory can hold a small 
amount of information from a few seconds to a minute without rehearsal.  Like sensory 
memory, short-term memory has a limited capacity, estimated at 3 to 9 elements.  Items 
held in short-term memory include: recently processed sensory input, recently retrieved 
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long-term memories, and the results of recent mental processing.  A special form of 
short-term memory, working memory, refers to the temporary storage and manipulation 
of information needed for language comprehension, learning, and reasoning (27).  
Working memory is unique in that it requires the simultaneous storage and processing of 
information.  Working memory can be generally divided into three subcomponents: 1. 
central executive, an attentional-controlling system important for problem solving tasks; 
2. visuospatial sketchpad, manipulates visual images; and 3. phonological loop, stores 
and rehearses speech-based information.  
 Long-term memory can store information for as little as a few days or as long as 
decades.  Unlike sensory and short-term memories, long-term memory has an unlimited 
capacity.  Short-term memory is supported by a temporary potentiation of neuronal 
connections, especially in the frontal and parietal lobes.  Specific patterns of neuronal 
connections distinguish different memories.  A stronger neuronal connection encoding a 
stimulus will result in a stronger associated memory.  Through rehearsal and association 
this temporary potentiation can be processed into long-term memory.  The proposed 
mechanism by which short-term memories move to long-term memory is via long-term 
potentiation (LTP), which results in physical changes in the structure of neurons.  Long-
term potentiation is the long lasting enhancement in communication between two neurons 
simultaneously stimulated (28, 29).  LTP shares several properties with long-term 
memory, making it a candidate for the cellular mechanism of learning.  Both LTP and 
long-term memory are rapidly induced, stimulus specific, rely on the formation of new 
proteins, and last for months following exposure to the original stimulus (30).  It is 
widely accepted that during long-term memory formation changes in protein synthesis 
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controls synaptic strength via rapid protein production from preexisting mRNA.  Protein 
synthesis is required for several forms of synaptic plasticity (31-34).  Synaptic plasticity 
is a physiological phenomenon whereby specific patterns of neural activity give rise to 
changes in synaptic efficacy and neural excitability that outlast the initial stimulus (35).  
It is thought that changes in synaptic patterns underlie the storage and recall of memory.   
Various neurotransmitters in the brain, including acetylcholine, γ-aminobutyric acid 
(GABA), adrenergic and glutamertergic systems have been shown to play a significant 
role in memory function (33-37).    
 Memory formation and storage involves complex communications between 
different cortical and subcortical structures of the brain, with no single site of memory 
formation and storage (38).  The cerebellum, the limbic system (hippocampus, amygdala 
and the thalamus) and the cortical areas of the brain have been associated with memory 
storage and retrieval (39).  Each structure has been associated with the encoding and 
retrieval of different memory types.  Clinical case in humans (40-43) and animal studies 
of hippocampal lesions (43-46) demonstrate the importance of the hippocampus in 
memory acquisition.  Specifically, it is thought that the hippocampus is important in 
short-term storage of sensory stimuli.  Following the initial stimulus, the hippocampus 
coordinates the spontaneous retrieval of different components of an experience and relays 
these unique components to different memory systems depending on the memory type 
(47).  Declarative memory is an aspect of human memory pertaining to the storage of 
facts, dates, and life events.  This type of information is relayed to perirhinal cortex and 
medial temporal lobe (48-50).  Memories of skills, procedural memory, is relayed to the 
striatum, neocortex, or to the cerebellum depending on the aspect of the skill.  The 
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cerebellum is involved in the storage of reflexes while the striatum and neocortex stores 
information about the skills.  
 Two memory types studied during cognitive testing in rodents include working 
memory and reference memory.  Working memory is defined as short term memory for 
an object, stimulus, or spatial location that is used within a testing session, but not 
typically between sessions.  This is distinguishable from a form of long-term memory 
termed reference memory, which is a memory that is typically acquired with repeated 
training, and would persist for days to months.  Reference memory is often the memory 
for the rules of a particular memory paradigm; for example, that an operant lever press 
produces a reward, or that a hidden platform is found in the Morris water maze.  Working 
memory is typically a delay-dependent representation of stimuli that is used to guide 
behavior within the task.  Working memory functions on a particular trial of a task, but 
then must be forgotten or ignored on subsequent trials (27).    
 Two major learning paradigms are commonly used in rodent studies of cognition.  
Conditional learning paradigms are used due to the ease of controlling the conditioned 
stimulus.  Spatial learning tasks are among the most commonly used tests for detecting 
potential cognitive enhancers and cognitive changes associated with aging.   
 Conditioned learning tasks can involve aversive or reinforcement stimuli.  
Avoidance tasks measure memory of an aversive event, through simple avoidance of the 
location in which the aversive stimulus was first experienced.   The animals avoid a 
location, (for example a dark room) where they previously received an aversive stimulus 
(foot shock).  An avoidance task can require either a passive or active response.  With a 
passive avoidance task an animal is placed in a lighted room; having a natural disposition 
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for the dark the rodent will leave the lighted room and enter the darkened room.  Once it 
enters the dark room a foot shock is administered, providing a stimulus which helps the 
animal learn on subsequent trials to stay in the lighted room.  When the aversive stimulus 
is made predictable the animal can then actively avoid the stimulus.  In an avoidance 
paradigm, task performance is measured by the ability of the animal to avoid the 
compartment where a shock has occurred during the training phase of the paradigm.  In 
reinforcement paradigms, animals can learn an operant lever press to gain access to an 
appetitive stimulus such as water or food.  
 In spatial learning tasks, the animal’s behavior can be driven either by an aversive 
stimulus where the goal is to find refuge (finding a platform in the Morris water maze 
task), by an appetitive stimulus (water or food), or by spontaneous choice exploration 
(novel arm versus familiar arm).  The Morris water maze requires rats to find the location 
of a submerged invisible platform in a large circular pool of water.  One version of the 
task that tests reference memory is typically run by submerging the platform in the same 
location in the pool across days.  The rat solves the task by learning the spatial 
relationships between the platform location and extramaze landmarks in the testing 
environment.  Evidence of the rat learning the location of the hidden platform is observed 
with a shorter time latency to swim to the platform during subsequent trials.  Working 
memory versions of this task have also been developed, with the location of the platform 
changed each day of testing.  Working memory versions of the water maze require the 
animal to remember the location of the hidden platform during multiple trials in a training 
day, but forget this location on the next day of training.  Again, evidence of the rat 
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learning the location of the hidden platform is seen with shorter latency to swim to the 
platform as the number of trials increase for that training day.    
 A classical task for testing memory in rodents is the radial arm maze.  The maze 
is comprised of a center platform with radiating arms (6-12 arms).  In this task, the rat is 
placed in the center platform, and a food reward is available at the ends of each of the 
arms.  Working memory is tested by determining the number of arms entered before all 
of the food reward is recovered.  It is observed that rats retrieve the food from each arm, 
and quickly learn to visit all the arms without re-entering a previously visited arm.  A 
version of the radial arm maze has also been developed to test working and reference 
memory at the same time.  In this version of the task, a predetermined number of arms 
are baited.  The same maze arms are baited each day, across sessions, the rats must learn 
to ignore the unbaited arms.  Entry into an unbaited arm is considered a reference 
memory error, while within a session re-entering a baited arm is considered a working 
memory error. 
 The T-maze task can be utilized to test delayed alternation or matching to position 
tasks.  Delayed alternation tasks rely on the rats’ tendency to choose alternative maze 
arms or locations when rats are re-exposed to the apparatus.  The task works as follows:  
a rat is placed into the base (start location) of the T.  The rodent runs up the stem of the 
maze and enters one arm of the T, where it then obtains a reward.  The rat is picked up by 
the observer and returned to the base of the T.  Typically the rat will run up the stem and 
enter the arm of the T that was not entered on the previous trial.  Rats tend to alternate 
without reinforcement; which is referred to as spontaneous alternation.   
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 A delayed matching to position task (DMP) can be used to offset the 
natural tendency of spontaneous alternation.  This task is performed in a similar way to 
the alternation task except on the second trial the animal must enter the same arm as 
previously entered in order to receive the food reward.  The DMP task typically requires 
more days of testing for the rodents to learn the task.  The animal must remember the 
initial response to repeat the response, thus this is a working memory task.  Typically, it 
is assumed that the rats solve the T-maze by remembering the location of the most 
recently visited arm based on its spatial relationship with extramaze cues.  Remembering 
the spatial relationship of cues to guide behavior is considered allocentric spatial 
memory.  The rat, however, may solve the task utilizing their directional sense, for 
example, first going east and then going west.  The rat may also remember which turn it 
has made (left) and make the opposite or same turn on the subsequent trial.  By doing 
this, the rat would adopt an egocentric strategy.  Egocentric strategy, also term response 
learning, involves rotating in a self centered spatial framework in response to a cue.  
Guidance strategy consists of approaching or avoiding an object or cue in the 
environment.  The use of this type of strategy is known as “cue learning”.  Finally, if 
subtle odor cues are left in the maze, the rat may detect the arm that was most recently 
entered by olfaction.  It is unlikely that animals use only one learning strategy during 
acquisition of a T-maze task.  It is more likely that learning in this task requires the 
adoption of multiple learning strategies during different periods of training.   
Neurons in the hippocampus code spatial location (41-42), and performance 
within the T-maze is particularly sensitive to the effects of hippocampal disruption (37-
40).  Damage to the hippocampus and its connections produce significant impairments in 
13 
 
many forms of the T-maze task.  Therefore, it is likely that damage to the hippocampus 
diminishes the ability of rodents to use spatial relationships in the environment to guide 
navigational behavior.  These animals could still use either egocentric or guidance 
strategies, which are mediated by non-hippocampal structures.   
 
3.  Overview of Acetylcholine as a Neurotransmitter: 
 Acetylcholine (ACh) is a major neurotransmitter in both the mammalian 
peripheral nervous system and mammalian central nervous system (CNS) (51).  Within 
the peripheral nervous system, acetylcholine is involved in the coordination of skeletal 
and smooth muscle contraction, control of heart rate, and regulation of endocrine gland 
secretions.  Within the central nervous system, acetylcholine is implicated in emotional 
and attentional processes, learning, memory, and arousal (51-55).   
 
Illustration 1:  The synthetic pathway for acetylcholine. 
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 Acetylcholine is synthesized in a reaction catalyzed by the enzyme choline 
acetyltransferase (ChAT) from acetyl coenzyme A (CoA) and choline. Acetyl CoA 
primarily arises from glucose in the mitochondria through glycolysis and the pyruvate 
dehydrogenase system; from citrate, either by reversal of citrate synthesis or by citrate 
cleavage; or from acetate through acetate thiokinase (56,57).  Following hydrolysis of 
ACh, 30-50% of the liberated choline is transported back into the presynaptic neuron 
through a high affinity choline transporter.  The remainder of the choline is catabolized or 
incorporated into phospholipids where it can be used as a future source of choline.  The 
uptake of choline is the rate limiting factor in the synthesis of ACh (56).  Acetylcholine 
esterase normally hydrolysizes acetylcholine into its inactive metabolites.  This enzyme is 
abundant in the synaptic cleft of neural tissue, and its role of clearing ACh from the 
synaptic cleft is essential for proper functioning of the cholinergic system (2, 56, 57).  
 Cholinergic receptors fall into two classes, muscarinic and nicotinic.  Currently 
five muscarinic receptors (M1-M5) have been identified, each produced by a different 
gene.  All muscarinic receptor subtypes are G-protein coupled metabotropic receptors 
that contain seven hydrophilic transmembrane domains, and transduce a signal that 
activates a number of second messenger systems.  The M1, M3, M5 receptors are coupled 
via Gq to phosphatidylinositol hydrolysis and M2 and M4 receptors via Gi are coupled to 
cyclic adenosine monophosphate.  The cellular effects of muscarinic receptor activation 
include either opening or closing of K+ channels, Ca2+ channels, or Cl- channels, 
depending on the receptor and cell type.  Therefore, the stimulation of muscarinic 
receptors can result in either depolarization or hyperpolarization of a neuron.   
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 The nicotinic ACh receptor is a pentameric integral membrane protein composed 
of five different polypeptide chains (α, β, γ, δ, ε).  To date 17 nicotinic ACh receptors 
have been identified, which are divided into muscle-type and neuronal-type subunits.  
Neuronal-type nicotinic receptors can be divided into two subtypes: 1.) the high affinity 
agonist binding class, which fails to bind α-bungerotoxin and is a heteropentameric 
nicotinic receptor formed by α2-α6 and β1-β4 subunits; and 2.) lower affinity binding 
class that binds α-bungerotoxin and is usually homopentameric formed by α7-α9 
subunits (51).  Acetylcholine binds to the α subunit causing a conformational change in 
the channel that selectively allows cations (Na+ and Ca+) to pass through the membrane, 
leading to a rapid depolarization and excitation.  Nicotinic receptors are located at 
skeletal neuromuscular junctions, autonomic ganglia, adrenal medulla and CNS (56,57). 
 
Illustration 2:  Cholinergic system of the rat brain.  Notice the major cholinergic 
innervation of the hippocampus by the medial septum.  ms- medial septum, vdb- vertical 
diagonal band of Broca, hbd- horizontal diagonal band of Broca, bas- nucleus basalis 
magnocellularis, si- substantia innominate , ppt- pendunculopotine, ldt- laterodorsal 
tegmental nuclei (51).    
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 The cholinergic system in the brain can be divided into four main components:  
the basal forebrain cholinergic system, pontine (brainstem) cholinergic system, motor 
neurons and cholinergic interneurons.  The basal forebrain and pontine cholinergic 
systems contain projection neurons connecting two or more different regions.  
Cholinergic interneurons are classified as local circuit cells, which are morphologically 
arranged within one neuronal structure, and are exemplified by the interneurons of the 
caudate putamen nucleus, nucleus accumbens, olfactory tubercle and islands of Calleja 
complex.  Motor neurons are located within the CNS and project their axons to the 
periphery where they directly or indirectly control muscle movements.   
Within the CNS, the motor neurons originate from the primary motor cortex, brain stem 
and cranial nerve nuclei.  The pontine cholinergic system contains cholinergic neurons in 
the pendunculopotine and laterodorsal tegmental nuclei, which project to the thalamus, 
pontine, other diencephalic loci, medullary formations and cranial nerves (58).   
 Acetylcholine containing neurons of the basal forebrain located in the nucleus 
basalis magnocellularis (NBM), the diagonal band of Broca (DBB) and the medial 
septum (MS), give rise to projection neurons innervating the cerebral cortex, the 
amygdala, the hippocampus and several thalamic nuclei (59-60).  The NBM contains the 
primary concentration of cholinergic neurons that project to the neocortex, while the 
DBB contains a cholinergic bundle of nerve fibers that interconnects the paraterminal 
gyrus, in the septal area, with the hippocampus and lateral olfactory area.  The 
septohippocampal tract is formed by the cholinergic projection neurons from the MS to 
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the hippocampus and provides the greatest cholinergic innervation of the hippocampus 
(59,60).                    
 It was observed that hippocampal ACh release increased during performance of a 
learned spatial memory task (61,62), and the improvement in radial arm maze 
performance was positively correlated to the increase in ACh release during 12 days of 
task learning (63).  These results demonstrated that the learning of the spatial task 
modified the function of cholinergic neurons projecting to the hippocampus, which 
become progressively more active.  Furthermore, spatial discrimination learning 
selectively increased muscarinic ACh receptor immunoreactivity in CA1-CA2 regions of 
the hippocampus, and in the neocortex, but not in the amygdala (64).   
 Memory processes are mediated by independent and/or competing parallel 
neuronal systems (for a review see 65).  It has been demonstrated that hippocampal ACh 
release increases both when rats are tested in a hippocampal dependent spontaneous 
alternation task and an amygdala dependent conditioned place preference (CPP) task 
(66).  The magnitude of hippocampal ACh release was negatively correlated with 
performance in the CPP task, indicating not only a competition between the two 
structures, but also that activation of the cholinergic hippocampal system inhibited the 
expression of amygdala dependent memory.  However, competition was not the only 
interaction between the hippocampus and the amygdala, because it has been reported that 
ACh release in the amygdala was positively correlated with performance in a 
hippocampal spatial working memory task (66).  The two structures seemed to have a 
nonreciprocal interaction in that the hippocampus competes with the amygdala, but the 
amygdala cooperates with the hippocampus during learning.   
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 In the plus maze task, the time course of ACh release in the hippocampus and the 
striatum differed during training.  The hippocampal cholinergic system was activated first 
during training and was involved in a place strategy depending on spatial memory; the 
striatal cholinergic system was activated later in training, when the rats shifted to 
response strategy to solve the maze (67).  Studies indicated that the cholinergic projection 
neurons may not only be important for learning but may also be important for attentional 
processes (68).  Microdialysis experiments indicated that cortical ACh increase during 
performance of a simple operant task was limited to early acquisition stages, when the 
attentional demand is high (69).  Similarly, large increases in cortical and hippocampal 
ACh release were observed during acquisition of a reward operant task, but not during 
recall of the task (70).  Intraparenchymal injections of a selective neurotoxin disrupted 
attentional processing in NBM- and MS-infused animals, thus confirming the role of the 
cholinergic system in attention (71).   
 
4.  Central Cholinergic Immunolesioning with SAP: 
 The cholinergic hypothesis of AD proposes that degeneration of cholinergic 
neurons in the basal forebrain and the associated loss of cholinergic neurotransmission in 
the cerebral cortex and hippocampus contribute significantly to the deterioration of 
cognitive function in AD patients (72).  To study the contributions of cholinergic basal 
forebrain neurons to the establishment of the cognitive features of AD, animal models are 
required that specifically mimic cholinergic cell loss in the basal forebrain and cortical 
cholinergic hypoactivity.  Classical methods that relied on fimbrial transactions, 
mechanical lesions, chemical injections of quisqualic acid, α-amino-3hydroxy-5-methyl-
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isoxazole-4-proprionic acid (AMPA) and ibotenic acid failed to induce complete and 
selective cholinergic cell death in the basal forebrain (72-74). The main reason for this 
complication was that cholinergic neurons of the basal forebrain are intermingled with 
GABAergic and other neurons, which have similar projection targets that also influence 
memory function.  Therefore, nonselective lesions confound the interpretation of the 
behavioral results from these animal models.     
 An understanding of the role of basal forebrain in learning and memory has 
accelerated since the development of immunotoxins such as 192-IgG-saporin (SAP).  
SAP provides a more efficient and selective tool to induce permanent cortical 
hypofunction.  The immunotoxin was constructed through a disulfide bond linkage of the 
monoclonal antibody 192IgG and the plant alkaloid saporin (75).  192IgG is a 
monoclonal antibody raised against the low affinity nerve growth factor receptor (p75 
NGF receptor), while saporin, obtained from Saponaria officinalis, is a potent ribosome-
inactivator (76).  p75 NGF receptors are extensively expressed on the soma and terminals 
of the cholinergic neurons of the basal forebrain (77).  This neurotoxic complex binds to 
the p75 NGF receptor found on cholinergic neurons of the basal forebrain.  Like the 
endogenous ligands for the p75 NGF receptor, the toxin is internalized after binding, and 
is reterogradely transported back to the soma (78).  The saporin toxin is cleaved from the 
antibody and escapes the endosome, allowing saporin to enzymatically inactivate the 
large ribosomal subunit of the protein complex.  Inactivation of this complex inhibits 
protein synthesis, ultimately leading to neuronal death (76).   
 Following ventricular injections, the immunotoxin is taken up by cholinergic 
neurons of the basal forebrain resulting in cholinergic losses in the MS, DBB, and NBM; 
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whereas, adjacent cholinergic neurons in the ventral pallidum and caudate putamen are 
spared (79).   The MS and DBB contain cholinergic and GABAergic neurons which both 
project to the hippocampus.  Ventricular injections had no effects on the GABAergic 
neurons of the basal forebrain, but affected purkinje fibers which also express p75 NGF 
receptors (79).  The latter needs to be considered during behavioral testing since 
destruction of the purkinje fibers have been associated with severe motor deficits in rats.     
 Histological experiments demonstrated that localized infusion of SAP into the 
three distinct loci of the basal forebrain resulted in a complete loss of NGF 
immunoreactive neurons within the areas of interest (80).  Following localized infusions 
of SAP, sections stained for a cholinergic marker, AChE, also showed a loss of 
cholinergic neurons in distinct loci.  A dramatic reduction of AChE staining in the target 
areas (dorsolateral neocortex, cingulated cortex and hippocampus) was associated with 
the distinct region of the basal forebrain which provides cholinergic innervation.  
Similarly ChAT activity in the targeted areas displayed reduced activity, further 
demonstrating cholinergic hypoactivity (81).  Localized infusion of SAP did not affect 
cholinergic neurons which lacked p75 NGF receptor expression.  Localized infusions of 
higher SAP doses (1 μg) directly into the basal forebrain induced lesions of all 
cholinergic neurons within the basal forebrain and other non-cholinergic neurons 
expressing p75 NGF receptors including the purkinje fibers (82).  Smaller doses of SAP 
(0.22 μg) injected directly into selected loci of the basal forebrain, like the MS, spared 
not only the purkinje fibers but also GABAergic neurons present in the MS (82).  Effects 
on GABAergic neurons should be considered because of the important role they play in 
regulating hippocampal function.  The intensity of staining for parvalbumin, a calcium 
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binding protein expressed by a subset of GABAergic neurons in the MS, is examined to 
detect changes in the population of GABAergic neurons present in the MS.  At the 0.22 
μg dose of SAP, there is no effect observed in the intensity of parvalbumin staining, 
compared to the decreased staining with higher doses of SAP (82).  Thus, injections of 
low doses of SAP directly into individual basal forebrain loci could provide an excellent 
tool for dissociating the role of cholinergic basal forebrain nuclei and their projections in 
mediating cognitive processes.   
 
5.  Role of Dehydroepiandrosterone and Dehydroepiandrosterone Sulfatase in 
Cognition: 
 
Illustration 2:  Structural relationship between dehydroepiandrosterone and its sulfated 
form 
 
 
 Dehydroepiandrosterone (DHEA) and its sulfated ester dehydroepiandrosterone 
sulfate (DHEAS) have gained significant interest in the field of neuroscience due to two 
findings:  a strong age associated decline of the steroid in humans and the demonstration 
of DHEA(S) metabolism and action in the rodent brain.  DHEAS is the most abundant 
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steroid product of the adult human adrenal cortex with concentrations in the microgram 
per milliliter range (83).  In addition to its adrenal origins, DHEA is also produced in 
small amounts (10-20% of circulating hormone) within the gonads and CNS (84,85).  
Formation of DHEA is stimulated by adrenocorticotropic hormone from the pituitary, has 
a short serum half-life (30 min. or less), and a serum concentrations that fluctuate 
markedly with the circadian rhythm.  DHEAS has serum concentrations greater than 200 
times that of DHEA and has a much longer half-life (7-10 hours), which largely removes 
the variation in plasma concentration associated with circadian rhythm (86-90).  Due to 
the short half life (30 min) and quick catabolism of DHEA, less than 1% of the steroid is 
in circulation as the unsulfated form (91).  Most of the DHEAS (60-80%) entering the 
blood is converted to DHEA by steroid sulfatase, while a small amount of DHEA (5-7%) 
is converted to DHEAS by hydroxysteroid sulfotransferase in the liver, kidney, and CNS, 
creating an equilibrium between the two isoforms (89, 92).  DHEA(S) exhibits a strong 
and unique developmental pattern. 
   
 
Illustration 3:  Unique developmental pattern for DHEAS  
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 DHEA is produced in the fetal adrenal glands, with concentrations sharply 
dropping and becoming almost undetectable 6 months following birth (93).  One to two 
years after puberty a rise in DHEA production occurs, with a peak concentration obtained 
during the third decade of life (83, 94-95).  Thereafter, a marked continuous decline in 
DHEA(S) concentration is observed with patients in their sixth decade of life, possessing 
only 20% of plasma concentrations compared to pubescent patients.  This developmental 
pattern is observed in both males and females, with males having higher DHEAS levels 
in adulthood (96-99). This strong age-associated pattern is not observed for cortisol, the 
primary human glucocorticoid secreted from the adrenal cortex, where basal levels are 
unchanged or slowly increase throughout the life-span (100, 101). 
 Neuroactive steroids are endogenous compounds with neuromodulatory effects 
(102).  Several of these compounds, such as estrogens and corticosterone, have been 
shown to enhance cognitive function in rodents and have gained significant interest as 
potential therapeutic regiments for dementia and age-associated memory loss (for a 
review see 103).  In the rodent brain, estrogen supplementation has been shown to 
enhance ChAT activity, high affinity choline uptake, and the release of ACh in the 
hippocampus following potassium stimulation (104-106).  Moreover, studies have 
demonstrated that estrogen supplementation can reduce the incidence and severity of 
Alzheimer’s disease in post menopausal women (107).   
 A subset of neuroactive steroids, termed neurosteroids, accumulates in the 
nervous system independent of the products of steroidogenic endocrine glands.  
Neurosteroids are synthesized de novo in the nervous system from sterol precursors.  
Neurosteroids have also been shown to modulate neuronal activity within the central 
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nervous system (102).  There is substantial evidence that DHEA and DHEAS are 
produced within the CNS and are therefore neurosteroids (102).  DHEA(S) 
concentrations in the rodent brain far exceed peripheral concentrations and are 
independent of adrenal synthesis (108, 109).  However, the exact metabolic pathway(s) 
for DHEA(S) in the rodent brain are still not completely understood, since P 450-17α (17 
α hydroxylase; the enzyme which converts pregnenolone into DHEA) is present in the 
fetal, but not in the adult rodent brain (110).  Furthermore, within the rodent brain there is 
a small amount of hydroxysteroid sulfotransferase activity.  These findings suggest that 
DHEA, which passes the blood brain barrier more readily than DHEAS, could be locally 
converted to DHEAS in the brain (111, 112).  Sulfatase activity is widely present in the 
CNS and its pharmacological inhibition affects memory (113-117).  Others have 
suggested an alternative pathway for the synthesis of DHEA in the central nervous 
system involving sterol and/or steroid hydroperoxides.  One study in primates reported 
high DHEAS levels in the brain that were not strongly suppressed by dexamethasone 
treatment, suggesting local biosynthesis (118).  Moreover, a postmortem study in human 
tissues demonstrated higher levels of DHEA and DHEAS in brain tissue compared to 
blood concentration, again suggesting local biosynthesis (119).                          
 Flood et al. were the first to show the memory-enhancing effects of DHEA and 
DHEAS, in both young (120-122) and old (123) mice using a foot shock paradigm.  In 
their extensive studies, multiple routes of administration (i.c.v., s.c., oral) were utilized, 
all leading to an inverted U-shaped dose response curve for memory-enhancing effects.  
Melchior and Ritzmann (124) demonstrated that when administered i.p., both DHEA and 
DHEAS enhanced short-term working memory as assessed with a T-maze paradigm.  
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Again, an inverted U-shaped dose response curve was observed.  Another group of 
experiments demonstrated that DHEAS enhanced memory when given before or directly 
after training, but not when administered before retention; suggesting that DHEAS 
enhanced the storage and/or consolidation of the learned paradigm but not retrieval (125).   
 Other studies have investigated the anti-amnestic properties of DHEA(S) using a 
variety of amnestic agents.  Flood et al. were again the first to show the anti-amnestic 
properties of excitatory neurosteroids using multiple routes of administration (120-122).  
Maurice et al. confirmed the antiamnestic effect of DHEA and DHEAS in mice utilizing 
multiple memory paradigms (Y maze, water maze, passive avoidance) with multiple 
amnestic agents (126-128).  Moreover, Maurice et al. demonstrated that DHEAS had 
effects on learning and/or storing information but no effect on recall of the same 
information (127).   
 DHEA(S) has memory enhancing and anti-amnestic effects on several brain 
locations associated with memory function, suggesting a global effect rather than actions 
limited to particular structures.  Paradigms utilized to show the memory enhancing 
effects of DHEA(S) rely on different neuronal structures, especially the hippocampus, the 
amygdala and frontal cortical regions (for review see 129).   
 Only one study reported memory impairment after DHEAS treatment (130).  
DHEAS administered orally for 5 days impaired hippocampal-dependent contextual fear 
conditioning, while having no effect on auditory cue fear conditioning.  Following 
adrenalectomy, similar effects were reported, providing evidence for an 
extraglucocorticoid action of DHEA.  The results of this experiment could be explained 
by a DHEAS-induced potentiation of the corticosterone response to a stressful test 
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paradigm, thus shifting the optimal corticosterone response, thereby impairing 
hippocampal plasticity.  This interpretation is supported by the observations that the 
identical DHEAS treatment enhanced memory performance in a T-maze memory 
paradigm (a less stressful task of hippocampal-mediated memory in rodents); thereby 
demonstrating that the memory impairing effects of DHEAS are only observed if the 
hippocampal meditated memory is tested under stressful conditions (131).  
 Since DHEA(S) concentrations decrease significantly with age in humans and 
multiple beneficial effects of DHEAS have been documented in rodents, many studies 
have investigated the relationship between DHEA(S) and cognition in humans. High-
functioning elderly patients, as defined by cognitive and functional examinations, possess 
higher DHEAS levels compared to patients in the median or lower functioning groups 
(132, 133). Lower DHEAS levels were also associated with poorer health, impaired 
global functioning, and physiological well being (134).  However, several short term 
studies found no beneficial effects of DHEA on well-being or cognitive performance in 
old or young adults (135, 136).  Recent studies have shown that among Alzheimer’s 
disease patients, those with higher concentrations of plasma DHEAS performed better on 
tests of association, digit span, and mini mental status exams when compared to those 
with lower levels of this neurosteroid (137).       
 The exact mechanisms by which DHEA(S) enhance memory function in the 
rodent remain unclear.  It appears that DHEA(S) acts primarily through interactions with 
cell surface neurotransmitter receptors.  This is in contrast to the classical actions of 
steroids that include: binding to an intracellular receptor, translocation to the nucleus, and 
binding to a response element resulting in altered protein synthesis.  The best documented 
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effects of DHEA(S) within the CNS are via negative modulation of the GABAA receptor 
complex (138-141).  This ligand-gated ion channel is a multimeric transmembrane 
receptor consisting of five subunits arranged around a central pore, which upon 
activation, increases chloride influx into the cell.  Imamua et al., demonstrated that 
DHEA and DHEAS noncompetitively inhibited GABA induced currents in cultured rat 
neurons with DHEAS being 3-4 times more potent than DHEA (142).  Moreover it was 
suggested that DHEAS may interact with the barbiturate sites on the GABAA receptor.  
Others have suggested picrotoxin as the DHEAS binding domain with DHEA having no 
effects on GABA currents (143).  There are several studies in rodents that show that 
GABAA antagonists enhance memory (144, 145) and their agonists impair memory (146, 
147).  These same effects are also relevant to humans, with benzodiazepines impairing 
cognition.     
 In addition to modulating GABAA currents, DHEAS also interacts with sigma 
receptors.  The sigma receptor (σ1 and σ2) is expressed in many tissue types, but is 
particularly concentrated in the CNS (148).  Many antipsychotic and antidepressant drugs 
have high binding affinity for the receptor (149).  Selective sigma agonists potentiate the 
response of rat CA3 dorsal hippocampal neurons to N-methyl-D-aspartate (NMDA) 
which suggests a functional link between the two receptor types.  The ability of sigma 
receptors to modulate NMDA mediated glutamatergic neurotransmission has been 
emphasized and proposed to play an important role in major neuro-adaptative events, 
such as long-term potentiation, learning and memory, and neurodegeneration (149-152).  
The first in vitro study for the role of DHEAS in modulating sigma receptors 
demonstrated that DHEAS (30mM or higher) potentiated NMDA evoked release of 
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norepinephrine from preloaded hippocampal slices (153).  Pertussis toxin, which 
inactivates Gi protein function, suppressed this effect of DHEAS (153).  Since σ1 but not 
σ2 receptors are coupled to Gi proteins, these results suggest that DHEAS modulates the 
NMDA response via the σ1 receptor.  These conclusions are further supported by a recent 
in vivo binding study in mice (154).  Sigma receptor agonists enhanced memory 
performance in several paradigms in young as well as in a model for cognitive aging in 
rodents (153, 154).  NMDA receptor involvement in memory is suggested by its 
important role in the development of long-term potentiation and the finding that NMDA 
receptor antagonists produce amnesia in both humans and rodents (143). 
 There are several possible pathways by which neurosteroids enhance memory 
function.  The GABAergic neurons of the nucleus accumbens are known to synapse upon 
cholinergic neurons of the MS which then form the major cholinergic projections to the 
hippocampus (155).  Therefore, DHEA(S) may enhance memory by disinhibiting the 
cholinergic neurons of the MS and increasing concentrations of acetylcholine in the 
hippocampus.  In support of this hypothetical pathway, peripheral administration of 
DHEAS enhanced hippocampal ACh release in vivo, and this enhancement occurred in a 
dose-dependent manner (155).  In further support of this hypothesis, Yoo et al. 
demonstrated a dose dependent increase in hippocampal long term potentiation following 
treatment with DHEAS (156).   
 
6.  Effects of Steroid Sulfatase Inhibitors on Learning and Memory  
 There is now good evidence that the metabolism of DHEA and its sulfated form 
occurs bi-directionally within the CNS, with DHEAS being desulfated via the enzyme 
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steroid sulfatase (108).  (p-O-sulfamoyl)-N-tetradeconoyl tyramine (DU-14) is a potent 
non-estrogenic irreversible inhibitor of steroid sulfatase.  A single dose of DU-14 (30 
mg/kg) was able to inhibit 95.2% of the steroid sulfatase activity within the liver (116).  
Furthermore, this treatment was able to significantly lower steroid sulfatase activity 
within the brain but at a substantially lower rate (14.8% reduction in activity) (116).  
Chronic treatments with DU-14 (30 mg/kg for 15 days i.p.) in rodents increased plasma 
concentrations of DHEAS, while decreasing plasma DHEA (113).  This same treatment 
also increased whole brain levels of DHEAS.   
 
 
Illustration 4:  Chemical structure of (P-o-sulfamoyl)-N-tetradeconoyl tyramine  
  
 The administration of DU-14 had been shown to increase hippocampal ACh 
release, a result which supports the findings that increased DHEAS levels in the brain 
augment the levels of ACh within the hippocampus (157).  Additionally, chronic 
pretreatment with DU-14 attenuated scopolamine induced spatial memory impairment in 
the passive avoidance paradigm and Morris water maze (116, 158).  In the Morris water 
maze not only did DU-14 reverse the scopolamine induced amnesia, but enhanced the 
performance of control animals (116).   In agreement with the GABA antagonistic action 
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of DHEAS, these findings suggested that DHEAS rather than DHEA was responsible for 
memory enhancement.  Since all of these experiments administered the steroid sulfatase 
inhibitor through an i.p. route, it remains unclear whether the observed effects were 
caused by actions of the inhibitor at the peripheral or central level.  It was hypothesized 
that DU-14 could also attenuate the cognitive deficit associated with lesion of septal-
hippocampal cholinergic projections.             
 
   
Illustration 5: Neurosteroid biosynthesis and metabolism in the rat brain.  Dotted arrows 
indicate metabolic conversion not yet formally demonstrated.  Note: figure is a 
modification of Figure 1 found in (226) 
 
 
7.  Effects of Aversive Stimulus and Stress on Spatial Learning 
 Emotional, aversive, and stressful experiences, via the activation of specific 
hormonal and brain systems, alter learning and memory processes (159-161).  Stress is a 
factor that is often overlooked when conducting research with laboratory animals.  Stress 
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exposure, depending on intensity and duration, can elicit either positive or negative 
effects on cognitive functions, particularly spatial learning and memory performance 
(162).  Stress-induced responses are largely mediated by the hypothalamic-pituitary-
adrenal (HPA) axis and result in increased plasma concentrations of both adreno-
corticotropic hormone and corticosterone, released from the anterior pituitary and adrenal 
cortex, respectively.  Short periods of mild stress (163-164) enhanced acquisition of 
certain spatial learning tasks, while longer periods of stress, or corticosterone treatment, 
impaired performance on a variety of spatial tasks (165-166).     
 The ability of stress to enhance performance of a spatial task may be due to the 
activation of pathways independent of the septal-hippocampal tract.  The glucocorticoids 
secreted in response to stress notably bind to mineralcorticoid and glucocorticoid 
receptors in the hippocampus.  Furthermore, epinephrine released from the adrenal cortex 
as a consequence of mild stressors that occur during a memory task can activate 
adrenergic receptors that facilitate memory function (167-169).  Adrenergic receptors 
found on vagal afferents project to the nucleus of the solitary tract and can subsequently 
activate neurons that project to the amygdala (164).  The amygdala has long been 
associated with the acquisition of memories related to aversive stimuli (170-174) and the 
modulation of memory processes of the hippocampus (175-177). 
   Based on these data, it is hypothesized that the mechanisms and pathways that 
underlie stress-induced enhancement of task performance, including spatial memory 
tasks, are distinct from the septal cholinergic neurons.  It is also hypothesized that the 
insertion of an aversive stimulus into a non-aversive DMP task could attenuate the deficit 
in acquisition previously observed from the lesion of septal cholinergic neurons.  This 
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could explain the lack of consistency in the literature regarding the importance of MS 
cholinergic neurons in spatial working memory.  Several studies have shown that 
selective destruction of the cholinergic neurons of the MS induced a marked decrease in 
acquisition of a spatial task (82, 105, 178).  Other investigations, though, have reported 
only limited effects of SAP lesions in the MS on spatial tasks.  For example, Dornan et 
al., (179) reported that a selective reduction of cholinergic transmission in the basal 
forebrain was by itself insufficient to account for the functional impairments in spatial 
learning of rats using a Morris water maze paradigm.  Baxter et al. (180, 181) utilizing a 
Morris water maze reported similar findings.  Therefore, a task with a mildly aversive 
component may preserve acquisition of a spatial task in animals with a septal-
hippocampal lesion via pathways that are independent of the septal-hippocampal tract.  
The result would be a loss of sensitivity in paradigms which involve a mildly aversive 
stimulus when assessing impairments in learning/memory associated with septal-
hippocampal lesion.  
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B.  Statement of the Problem 
 Alzheimer’s disease, the most common form of dementia, is a progressive 
neurodegenerative disorder characterized by memory loss and behavioral changes. 
Decreases in acetylcholine levels in multiple memory systems like the hippocampus and 
cortical regions of the brain have been implicated in the pathogenesis of Alzheimer’s 
disease.  Currently, animal models used to study the effects of cholinergic hypofunction 
on learning and memory formation are limited.  Animal models must be developed which 
can mimic the cholinergic hypofunction seen early in the pathology of many forms of 
dementia.   Once these models are developed, detailed studies are needed to determine 
the importance of cholinergic projections to the hippocampus and other cortical regions 
for learning and memory processes. 
 The current therapies of choice for dementia are anticholinesterase agents, which 
increase synaptic acetylcholine levels by inhibiting the enzyme acetylcholinesterase.  
However, these treatments provide only symptomatic relief and are ineffective in treating 
the disease itself.  DHEAS, a neurosteroid, replacement has been shown to be effective in 
reversing memory deficits associated with scopolamine induced amnesia.  Furthermore, 
preventing the conversion of these neurosteroids, especially DHEAS, to the unsulfated 
form can enhance memory function.  No study has thus far investigated the effect of 
DHEAS treatment on impairments in acquisition of a spatial task due to loss of septal-
hippocampal cholinergic neurons.  Furthermore, it has yet to be determined whether 
preventing the conversion of these neurosteroids to the unsulfated form through chronic 
administration of a steroid sulfatase inhibitor can attenuate the cognitive deficits 
associated with the selective loss of septal-hippocampal cholinergic projections. 
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C.  Hypothesis and Aims 
1.  Hypothesis 
A selective loss of cholinergic neurons projecting to the hippocampus from the medial 
septum results in diminished acquisition of a delayed matching-to-position T-maze 
paradigm.  DHEAS, through direct administration or prevention of its conversion to an 
unsulfated form, will improve acquisition of the delayed matching-to-position T-maze 
paradigm independent of cholinergic projections to the hippocampus. 
 
2.  Specific aims 
1.  Examine the changes in the acquisition of a delayed matching-to-position T-maze 
paradigm following selective cholinergic immunolesion of the medial septum with 192 
IgG-saporin. 
 
2.  Examine changes in the adoption of different learning strategies in a spatial T-maze 
task following selective cholinergic immunolesion of the medial septum with 192 IgG-
saporin. 
 
3.  Examine the ability of DU-14 to attenuate cognitive deficits produced by the 
destruction of cholinergic neurons projecting to the hippocampus utilizing delayed 
matching-to-position T-maze paradigm.  
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4.  Examine the ability of DHEAS to attenuate cognitive deficits produced by the 
destruction of cholinergic neurons projecting to the hippocampus utilizing delayed 
matching-to-position T-maze paradigm.   
 
5.  Examine the effects the introduction of an aversive stimulus into the appetitive T-
maze paradigm has on the acquisition in rats with a selective 192 IgG-saporin lesion of 
the medial septum.   
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II. MATERIALS AND EQUIPMENT 
 
1.  Facilities 
Laboratories – Richard King Mellon Hall of Science, Room 416a 
  Bayer Learning Center, Animal Facility 
 
Office – Richard King Mellon Hall of Science, Room 420 
 
 
2.  Laboratory Animals 
 
300 – 350 gram Male Sprague-Dawley Rats 
Hilltop Lab Animals Inc., Scottdale, PA 
 
 
3.  Chemicals and Drugs   
 
192 IgG-saporin 
Chemicon, Temecula, CA 
 
Artificial Cerebral Spinal Fluid 
CMA Inc., North Chelmsford, MA 
 
Veterinary Sterile Saline 
Henry Schein, Melville, NY 
 
Veterinary Sterile Water 
Henry Schein, Melville, NY 
 
Pentobarbital 
 
Triadine Solution 
Stoelting Co., Wood Dale, IL 
 
Surgilube Surgical Lubricant 
Stoelting Co., Wood Dale, IL 
 
Isopropyl Alcohol 
Eckerd, Pittsburgh, PA 
 
Ethanol 
Fischer Scientific, Pittsburgh, PA 
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Mazola Corn Oil 
Giant Eagle, Pittsburgh, PA 
 
Acetaminophen 
Sigma Chemical Co., Saint Louis, MO 
 
Neosporin Antibiotic Ointment 
Lab Safety Supply Inc., Janesville, WI 
 
Dehydroepiandrosterone sulfate 
Sigma Chemical Co., Saint Louis, MO 
 
(P-o-sulfamoyl)-N-tetradeconoyl tyramine (DU-14) 
Gift from Pui-Kai Li at Ohio State University 
 
Saline Tablets 
Sigma Chemical Co., Saint Louis, MO 
 
Ethylenediaminetetraacetic acid (EDTA) 
Sigma Chemical Co., Saint Louis, MO 
  
Triton X-100  
Sigma Chemical Co., Saint Louis, MO 
 
3[H] acetyl-CoA 
Sigma Chemical Co., Saint Louis, MO 
  
Choline chloride 
Sigma Chemical Co., Saint Louis, MO 
  
Physostigmine sulfate 
Sigma Chemical Co., Saint Louis, MO 
  
Sodium Chloride 
Sigma Chemical Co., Saint Louis, MO 
   
Sodium phosphate buffer 
Sigma Chemical Co., Saint Louis, MO 
  
Acetonitrile 
Sigma Chemical Co., Saint Louis, MO 
  
Tetrephenylboron 
Sigma Chemical Co., Saint Louis, MO 
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EconoFluor scintillation cocktail  
Packard Instruments, Meriden, CT 
 
 
4.  Materials 
 
Hamilton 7000 5.0 μl Microsyringe 
Stoelting Co., Wood Dale, IL 
 
Tungsten Micro Drill 
Stoelting Co., Wood Dale, IL 
 
Nylon Monofilament Sutures 
Stoelting Co., Wood Dale, IL 
 
Original Perry Style Sterile Surgical Gloves 
Stoelting Co., Wood Dale, IL 
 
Surgical Mask 
Stoelting Co., Wood Dale, IL 
 
Bouffant Caps 
Stoelting Co., Wood Dale, IL 
 
Shoe Cover 
Stoelting Co., Wood Dale, IL 
 
NU Gaze 
Stoelting Co., Wood Dale, IL 
 
Sterile Cotton Tipped Applicators 
Stoelting Co., Wood Dale, IL 
 
Disposable Sterile Surgical Drape 
Stoelting Co., Wood Dale, IL 
 
Sterilizing Pouches 
Stoelting Co., Wood Dale, IL 
 
Dissecting Forceps 
Stoelting Co., Wood Dale, IL 
 
Micro-Dissecting Retractors 
Stoelting Co., Wood Dale, IL 
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Micro Dissecting Scissors 
Stoelting Co., Wood Dale, IL 
 
Bone Ronguers 
Stoelting Co., Wood Dale, IL 
 
Needle Holder 
Stoelting Co., Wood Dale, IL 
 
Scalpel Blades (#10) 
Stoelting Co., Wood Dale, IL 
  
Scalpel Handlers 
Stoelting Co., Wood Dale, IL 
 
Pipetman Pipettes 
Fisher Scientific, Pittsburgh, PA 
 
BD Falcon Conical Tubes (50, 15 ml) 
Fisher Scientific, Pittsburgh, PA 
 
Eppendorf tubes (0.6, 1.5 ml) 
Fisher Scientific, Pittsburgh, PA 
 
BioRad Protein Assay 
BioRad, Hercules, CA 
 
Scintallation Vials 
Fisher Scientific, Pittsburgh, PA 
 
Fisherbrand Redi-Tips disposable pipette tips (200, 1000μl) 
Fisher Scientific, Pittsburgh, PA 
 
BD syringe (1.5, 10ml) 
Fisher Scientific, Pittsburgh, PA 
 
Disinfecting Cleaner 
Lab Safety Supply Inc., Janesville, WI 
 
FEP Tubing 
CMA Inc., North Chelmsford, MA 
 
Infusion Probe 
CMA Inc., North Chelmsford, MA 
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Reward Pellets 
Research Diets, New Brunswick, NJ 
 
LabDiet Rodent Chow 
Purina Mills, St. Louis, MO 
 
 
5.  Equipment 
 
Accumet pH Meter, Model 291 
Fisher Scientific, Pittsburgh, PA 
 
Themolyne Nuova Stirrer 
Fisher Scientific, Pittsburgh, PA 
 
Fisher Scientific Accu-124 Scale 
Fisher Scientific, Pittsburgh, PA 
 
Revco Freezer (-80°C) 
Revco Thermo Electron Corporation, Asheville, NC 
 
Whirlpool Refrigerator 
Whirlpool Corp., Benton Harbor, MI 
 
Autoclave 
 
Lab Standard Stereotaxic Instrument 
Stoelting Co., Wood Dale, IL 
 
Infusion Syringe Pump 
Stoelting Co., Wood Dale, IL 
 
Germinator Dry Sterilization 
Stoelting Co., Wood Dale, IL 
 
Rodent Brain Matrices (large coronal rat) 
Stoelting Co., Wood Dale, IL 
 
Decapitator 
Stoelting Co., Wood Dale, IL 
 
Homeothermic Blankek for Rodents 
Stoelting Co., Wood Dale, IL 
 
Surgical Clippers 
Stoelting Co., Wood Dale, IL 
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Rotating T-Maze 
Consists of: Approach alley: 4” wide x 14” long  
  Two Goal Arms:  4” wide x 12” long 
  Black acrylic walls 5” high 
  Clear acrylic hinged top 
  Mounted to a “Lazy Susan”  
 
Sonicator 
Fisher Scientific, Pittsburgh, PA 
 
Liquid Scintillation Counter 
Packard Instruments, Meriden, CT 
 
UV/VIS Spectrophotometer 
Beckman Instruments, Fullerton, CA 
 
6.  Computer Software 
 
Graphpad Prism 3.0 
Graphpad, San Diego, CA 
 
Microsoft Excel, Microsoft Office XP 
Microsoft Corporation, Orem, UT 
 
Microsoft Word, Microsoft Office XP 
Microsoft Corporation, Orem, UT 
 
Microsoft Photoshop, Microsoft Office XP 
Microsoft Corporation, Orem, UT 
 
Microsoft PowerPoint, Microsoft Office XP 
Microsoft Corporation, Orem, UT 
 
Adobe Photoshop Version 5.0 
Adobe Sytems, Seattle, WA 
 
Adobe Acrobat (Reader and Writer) 
Adobe Sytems, Seattle, WA 
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III. EXPERIMENTS 
 
A.  Effects of medial septum cholinergic lesions on ChAT activity. 
 
1. Introduction 
 SAP is a powerful immunotoxin that has been shown to selectively destroy the 
p75 NGF receptor expressing neurons that are extensively expressed on the soma and 
terminals of the cholinergic neurons of the basal forebrain (75,77).  Histological 
experiments demonstrated that localized infusion of SAP into the three distinct loci of the 
basal forebrain resulted in a complete loss of NGF immunoreactive neurons within the 
area of interest (80).  Following localized infusions of SAP, sections stained for a 
cholinergic marker, AChE, showed a loss of cholinergic neurons in the distinct loci.  
Furthermore, there was a dramatic reduction of AChE staining in the target areas 
(dorsolateral neocortex, cingulated cortex, and hippocampus) associated with these 
distinct loci of the basal forebrain.  Similarly, ChAT activity in the targeted areas 
displayed reduced activity, further demonstrating decreased cholinergic innervation (81).  
Smaller doses of SAP (0.22 μg) injected directly into selected loci of the basal forebrain, 
like the MS, spared not only the purkinje fibers but also GABAergic neurons present in 
the MS (82).  Therefore, we hypothesized that low doses of SAP can be used to 
selectively destroy the cholinergic neurons of the MS.  We evaluated whether infusions 
of SAP (0.22 μg) into the MS significantly lowered the ChAT activity in the 
hippocampus, while displaying no effect on frontal cortex ChAT activity.  These results 
will validate the selective loss of cholinergic neurons present in the MS and the sparing 
of the cholinergic neurons in the NBM following the SAP infusion.  ChAT activity in the 
hippocampus and frontal cortex was also used to determine correct placement of the 
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cannula during the SAP lesioning process.  We predicted that small dose of SAP (0.22 
μg) infused directly into the MS will result in complete loss of cholinergic innervation of 
the hippocampus from the MS.  Infusions of small doses of SAP can then be used as a 
model to explore the importance of the MS cholinergic innnervation of the hippocampus 
in different learning and memory tasks.  SAP treated animals that did not show selective 
loss of ChAT activity in the hippocampus were excluded from subsequent studies.    
 
2. Methods 
i. 192 IgG-saporin Immunolesioning: 
 All experiments followed the guidelines of the N.I.H. for the care and use of 
laboratory animals and were approved by the Duquesne University Institutional Animal 
Care and Use Committee.  Male Sprague-Dawley rats weighing between 300 and 350 
grams were obtained from Hilltop Lab Animals (Scottdale, PA).  Male rodents were 
chosen so that influences of estrogens on learning and memory were minimized.  
Animals were housed individually in a temperature and humidity controlled facility on a 
12:12 h light:dark cycle with unrestricted access to food and water.  For intraseptal 
infusion, animals were anesthetized with pentobarbital (50mg/kg; IP) and placed into a 
stereotaxic frame.  An incision was made exposing the dorsal aspect of the skull and a 
hole was drilled over the medial septum (MS; +0.2 bregma, 0.0 lateral).  A stainless steel 
cannula was lowered 5.6mm from the dura into the MS.  Animals were infused with 
either 1 μl vehicle (artificial cerebral spinal fluid [aCSF]) or SAP (0.22μg in 1 μl of 
aCSF) over 5 min. at a rate of 0.2μl/min.  The dose of SAP was selected based on 
previous studies using the same lot number (Advanced Targeting Systems; Lot #24-87) 
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that demonstrated a substantial loss of cholinergic neurons in the MS with little 
nonselective damage to GABAergic neurons (82).  Following infusion, the cannula 
remained in place for 5 min. to allow for diffusion of the solution into the tissue, and 
prevent the removal of SAP from the intended injection site.  The incision was sutured 
closed and animals were allowed to recover for 2 weeks before initiating behavioral 
testing. 
 
ii. Choline Acetyltransferase Assay (ChAT): 
 The degree of cholinergic deafferentation was assessed by measuring ChAT 
activity within the hippocampus and frontal cortex.  After completing all training, 
animals were anesthetized with pentobarbital (100mg/kg; IP) and perfused with ice cold 
saline.  The brains were removed, and tissues from the hippocampus and frontal cortex 
dissected, frozen, and stored at -80°C until processed for ChAT activity as previously 
described (82).  Frozen tissues were thawed and dissociated by sonication in a medium 
containing EDTA (10mM) and Triton X-100 (0.5%) and diluted to a concentration of 
10mg tissue/ml.  An aliquot of each sample was used for the determination of total 
protein (186).  Three 5μl aliquots of each sample were incubated for 30 min. at 37°C in a 
medium containing 3[H] acetyl-CoA (50,000-60,000d.p.m./tube, final concentration 
0.25mM acetyl-CoA), choline chloride (10.0mM), physostigmine sulfate (0.2mM), NaCl 
(300mM), sodium phosphate buffer (pH 7.4, 50mM), and EDTA (10mM).  The reaction 
was terminated with 4 ml sodium phosphate buffer (10mM) followed by the addition of 
1.6mL of acetonitrile containing 5mg/ml tetraphenylboron.  The amount of 3[H] 
acetylcholine produced was determined by adding 8 ml of EconoFluor scintillation 
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cocktail and counting total cpms in the organic phase using an LKB beta-counter. 
Background was determined using identical tubes to which no sample was added.  The 
three reaction tubes containing sample were averaged and the difference between total 
cpms and background cpms was used to estimate the total amount of ACh produced per 
sample.  Cholineactyltransferase activity was then calculated for each sample as pmol 
Ach synthesized/hr/μg protein.         
 
iii.  Statistical Analysis: 
 Due to the large number of samples, ChAT assays were completed with multiple 
runs, with each run containing samples from different treatment groups and normalized to 
percent change from controls.  Differences in ChAT activity for the hippocampi of 
treatment groups were determined using one-way ANOVA.  All analyses were performed 
using GraphPad Prism 3.0. 
   
3.  Results 
 Levels of ChAT activity are summarized in Table 1a and 1b.  As expected, 
infusion of SAP (0.22μg/μl) into the medial septum (MS) resulted in a significant 
decrease in ChAT activity within the hippocampus, demonstrating a loss of cholinergic 
afferents from the MS to the hippocampus.  There was a 70.5% decrease in ChAT 
activity in the hippocampi of SAP-MS treated rats compared to control animals.  (7.85 ± 
1.37 versus 26.61 ± 0.77 pMol ACh/h/μg protein; p < 0.001).  There was no significant 
difference in ChAT activity between treatment groups for tissues collected from the 
frontal cortex (p = 0.26).       
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Table 1a:  ChAT activity in aCSF-treated control animal 
 Range Means ± s.e.m. 
Hippocampus (n=45) 25.03 – 31.10 26.61 ± 0.77 
Frontal Cortex (n=45) 27.21 – 40.92 34.12 ± 3.06 
Values expressed as pMol ACh produced/h/μg protein. 
 
Table 1b:  ChAT activity in SAP-MS treated animal 
 Range Means ± s.e.m. 
Hippocampus (n=42) 3.83 – 13.34 7.85 ± 1.37 
Frontal Cortex (n=42) 22.24 – 44.83 30.01 ± 3.62 
Values expressed as pMol ACh produced/h/μg protein. 
 
 
4.  Discussion 
 
 The ChAT assay results demonstrated that infusion of SAP (0.22μg/μl) into the 
MS resulted in a significant decrease of ChAT activity within the hippocampus, but not 
in the frontal cortex (Table 1a-1b).  This finding is consistent with previous studies that 
showed a substantial loss of cholinergic neurons in the medial septum, but not in the 
nucleus basalis magnocellularis (NBM) using the same infusion protocol (82, 187, 188).  
The selectivity of SAP for cholinergic neurons in the MS has been questioned.  High 
doses of SAP injected into the lateral ventricles led to the loss of non-cholinergic 
p75NTR-expressing neurons located in distal from the infusion site (197).  Many of these 
distal effects were avoided by infusing small amounts of SAP directly into the MS.  Since 
GABAergic innervation of the hippocampus plays an important role in regulating 
hippocampal function it is important to select a dose of SAP that will not affect other 
neuron types at the site of infusion.  Parvalbumin is a calcium binding protein that serves 
as a marker for GABAergic neurons.  Previous studies have shown that the dose 
(0.22μg/μl) from the lot of SAP used in the present study had little effect on GABAergic 
parvalbumin-containing neurons located in the same regions of the MS (82).  Therefore, 
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it is concluded that any learning deficits observed in SAP treated groups are the 
consequence of a selective septal-hippocampal cholinergic lesion.  SAP treated animals 
that did not display selective destruction of the MS cholinergic neurons were eliminated 
from all subsequent experiments.  
 
B.  Effects of medial septum cholinergic lesions on spatial performance. 
 
1. Introduction 
 To study the contributions of cholinergic basal forebrain neurons to the 
establishment of the cognitive features of AD, animal models are required that 
specifically mimic cholinergic cell loss in the basal forebrain and cortical cholinergic 
hypoactivity.  This experiment was designed to better understand the role of the 
cholinergic projections from the MS during learning and memory.  Several studies have 
shown that selective destruction of the cholinergic projections from the MS induced a 
marked decrease in acquisition of a spatial task (82, 105, 178).  However, other 
investigations have reported only limited effects of SAP lesions in the MS on spatial 
tasks.  For example, Dornan et al., (179) reported that a selective reduction of cholinergic 
transmission in the basal forebrain was by itself insufficient to account for the functional 
impairments in spatial learning of rats using a Morris water maze paradigm.  Baxter et al. 
(180, 181) utilizing a Morris water maze reported similar findings.  It is possible that 
other tests may be more sensitive for detecting cognitive deficits associated with the 
selective loss of cholinergic projections from the MS, particularly tests which assess 
learning as opposed to working memory and retention.  We hypothesized that a selective 
loss of cholinergic neurons projecting to the hippocampus from the MS results in 
diminished acquisition of a DMP T-maze paradigm.  We predict that SAP treated animals 
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will take significantly more days to reach criterion and acquire the DMP task at a 
significantly slower rate.  If learning and memory deficits are observed following SAP 
lesioning of the MS, this could serve as a model to test drug therapies targeted at 
attenuating these memory deficits.  Furthermore, this can be used as a model to determine 
the importance of the MS cholinergic neurons in AD pathology.      
 
2. Methods 
 Immunolesioning of the cholinergic neurons of the MS with SAP was performed 
as documented in Experiment A.  All animals were allowed to recover 2 weeks following 
surgery before initiation of the behavioral testing.  Following behavioral testing ChAT 
activity in the hippocampus and frontal cortex was determined for each animal as 
described in Experiment A.  SAP treated animals that did not show selective decrease in 
ChAT activity within the hippocampus were eliminated from the study. 
   
i. Dietary Restriction- 
  
 Following surgery animals remained on an ad libitum diet.  The day before the 
first session of T-maze acclimation, all food was removed from the housing cages.  Diet 
restrictions began by feeding the animals 4 pieces of Rodent Chow (~8 g) after 
completion of the T-maze acclimation.  Weight was monitored daily, adjusting the 
amount of chow so that the animal maintained ~85% of normal body weight throughout 
the study.  A control animal fed ad libitum was included with each experimental group to 
ensure that the weights of the experimental animals did not exceed 85% of a normal age 
matched controls.    Animals were fed after completion of T-maze activities.    
49 
 
 ii. Behavioral testing: 
 The delayed match-to-position (DMP) task was performed as recently described 
(82, 182, 183).  All behavioral testing was performed between 10:00 a.m. and 2:00 p.m., 
seven days a week, except following the introduction of the probe trial.  During the probe 
trial a morning session (9:00 a.m. to 12 p.m.) and afternoon session were both performed 
(2:00 p.m. to 5 p.m.).  The order of testing for the different groups of animals was 
changed daily.  DHEAS displays minimal variation in plasma concentration associated 
with circadian rhythm, while DHEA has a short serum half-life and serum concentrations 
that fluctuate markedly with the circadian rhythm (86-90).  Varying the order by which 
the animals were tested minimizes the impact that variations due to circadian rhythms of 
DHEA and other neuroactive steroid levels has on learning and memory.   
 
T-maze Acclimation: 
 Acclimation began by scattering ten reward pellets throughout the T-maze with 
all doors of the T-maze opened.  Randomly paired animals were placed into the T-maze 
for 10 minutes.  Before running the next pair of animals, the T-maze was cleaned with a 
non-toxic spray disinfectant. 
 On the second day of acclimation, ten reward pellets were scattered throughout 
the T-maze and all doors of the T-maze remained open.  Sweetened rodent chow (50 mg, 
sucrose sweetened chow) was used throughout all experiments as the reward pellet.    
Animals were placed individually into the T-maze for 5 minutes.  Again, the T-maze was 
cleaned with a non-toxic spray disinfectant following each acclimation session. 
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     On days three through five of acclimation, four reward pellets were placed in each 
goal arm of the T-maze (total of 8 pellets) and all doors of the T-maze remained open.  
Animals were placed individually into the T-maze for 5 minutes or until all 8 pellets were 
eaten.   
 Animals were then trained to run to the ends of each goal arm by using a series of 
6 forced choices on days six through eight of acclimation. Animals were placed 
individually into the start box of the T-maze with the approach alley door and one goal 
arm door closed.  After 10 seconds of confinement in the start box, the approach alley 
door was opened, allowing the animal to explore the maze.  Once the animal entered the 
open goal arm, 2 reward pellets were dropped into this arm.  The animal was allowed to 
explore the T-maze for 90 seconds or until both reward pellets were eaten.  After each 
trial pair, animals were returned to their housing cages for 5-10 minutes, while training 
proceeded on the remaining animals of the group.  To avoid the introduction of a side 
bias, right and left goal arms were alternated in a random and balanced fashion according 
to the below list. 
 
 DAY 6    DAY 7    DAY 8   
 Left    Right    Left 
 Right    Left    Left 
 Left     Right    Right 
 Right    Left    Right 
 Left    Right    Left 
 Right    Left    Right 
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Delayed Match-to-Position Task Testing: 
 The DMP task was chosen to offset the natural tendency for spontaneous 
alternation observed in rodents (184, 185).  Animals were placed individually into the 
start box of the T-maze with the approach alley door and one goal arm door closed.  After 
10 seconds, the approach alley door was opened allowing the animal to move out of the 
start box and down the alley.  Once the animal entered the open goal arm, 2 reward 
pellets were placed in the arm.  The animal was allowed to explore the T-maze for 1 
minute or until both reward pellets were eaten.  The animal was then immediately 
returned to the start box and the maze was cleaned with nontoxic disinfectant spray to 
remove any odor cues.  Both goal arm doors were opened followed by the approach alley 
door.  The rodent was allowed to explore the T-maze for 1 minute or until it entered a 
goal arm.  If the animal entered the same physical goal arm (correct choice) that it 
explored during forced choice, 4 reward pellets were placed in the arm.  After the animal 
had eaten the pellets, it was returned to its housing cage for 5 to 10 minutes while training 
on the remaining animals in the group was finished.  If the animal entered the opposite 
goal arm (incorrect choice) as sampled during the forced choice, the goal arm door was 
closed and the animal was confined to that goal arm for 30 seconds.  After the 30 seconds 
of confinement, the animal was returned to its housing cage for 5 to 10 minutes while 
training on the remaining animals in the group was finished.  Animals continue to receive 
eight trials per day until a criterion of 15 correct choices out of 16 consecutive trial pairs 
were met.   
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The following is the pattern in which all animals were run during DMP acquisition. 
 
DAY 1:  Left    DAY 2:  Right  DAY 3:  Right 
    Left       Left       Left    
    Right      Right      Right 
    Right      Left       Left 
    Left       Right      Right 
    Left       Left       Left 
    Right      Right      Left 
    Right      Left       Right 
 
DAY 4:  Right  DAY 5:  Left    DAY 6:  Right 
    Right      Right      Left 
    Left       Left       Left 
    Left       Left       Right 
    Right      Right      Left 
    Right      Left       Right 
    Left       Right      Left 
    Left       Right      Right 
 
DAY 7:  Left   DAY 8:  Left   DAY 9:  Right 
    Right      Left       Left 
    Right      Right      Right 
    Left       Right      Left 
    Right      Left       Right 
    Left       Right       Right 
    Left       Left       Left 
    Right      Right      Left 
 
 
DAY 10:  Right  DAY 11:  Left   DAY 12:  Right 
      Left         Right        Right 
      Right        Right        Left 
                Left         Left             Left 
      Left         Right        Right 
       Right        Right          Left 
      Right        Left         Left 
      Left         Left         Right 
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DAY 13:  Right  DAY 14:  Left   DAY 15:  Left 
      Right        Left         Right 
      Left         Right        Right 
      Right        Left         Left 
      Left         Right        Left 
      Left         Left         Right 
      Right        Right        Left 
      Left             Right                 Right 
 
DAY 16:  Left   DAY 17:  Right  DAY 18:  Left 
      Right        Left         Left 
      Left              Right        Right 
      Right        Left         Right 
      Right        Left         Left 
      Left         Right        Right 
      Left         Left         Right 
      Right        Right        Left 
 
DAY 19:  Left   DAY 20:  Left   DAY 21:  Right 
      Right        Left         Right 
      Right        Right        Left 
      Left         Left         Right 
      Left         Right        Left 
      Right        Right        Right 
      Right        Left         Left 
      Left         Right        Left 
 
DAY 22:  Left   DAY 23:  Right  DAY 24:  Right 
      Right        Left         Left 
      Left            Left         Right 
      Right        Right        Right 
      Right        Left         Left 
      Left         Right        Right 
      Right        Right        Left 
      Left         Left         Left 
 
DAY 25:  Right  DAY 26:  Left   DAY 27:  Right 
      Left         Right        Left 
      Left         Left         Right 
      Right        Left         Right 
      Right        Right        Left 
      Left         Right        Left 
      Right        Left         Right 
      Left         Right          Left 
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DAY 28:  Left    DAY 29:  Right    DAY 30:  Right 
      Right        Left         Left 
      Left         Right        Left  
      Right        Right        Right 
      Left         Left         Right 
      Right        Left         Left 
      Left         Right        Left 
      Right        Left         Right 
 
iii. Statistical Analysis:  
 Days to criterion were analyzed using Student's T-test for individual comparisons 
of the two treatment groups. To compare treatment effects during different stages of 
acquisition, performance data was blocked into 3-day periods of training.  After an 
animal had reached criterion, a value of 93.75% (15/16) was recorded for performance on 
subsequent days.  Performance during acquisition testing was analyzed using two-way 
ANOVA for overall effects of block and treatment and Student's T-test for treatment 
effects within blocks.  Both the rate of performance and days to reach criterion in the 
DMP t-maze task was determined to be parametric.  Power analysis and variability seen 
in similar studies (82, 188) suggests that 8 animals per treatment group were enough to 
determine statistical significance.  All analyses were performed using GraphPad Prism 
3.0. 
 
3.  Results 
 Of the original 19 animals, all but two animals failed to reach criterion on the 
delayed matching to position (DMP) task or displayed a side bias and were excluded 
from the study.  One of the two animals was an aCSF control animal while the other 
received SAP lesioning of the MS.  Analysis of the remaining animals (8 control animals 
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and 9 SAP) indicated that SAP treated animals required more days to reach criterion (Fig. 
1).  Control animals took an average of 16.00 ± 1.195 days while the animals that 
received SAP lesioning of the MS took an average of 21.56 ± 3.779 to complete the DMP 
task.  Mann-Whitney non-parametric U-test showed a significant effect on treatment (p = 
0.001), indicating that SAP treated animals differed significantly from the aCSF treated 
control animals. 
 Examining of the learning curves (Fig. 2) showed that all animals performed at 
similar levels, below chance, at the start of DMP training and SAP treated animals 
improved at a slower rate when compared to aCSF-treated controls.  Analysis of the 
learning curves by two-way ANOVA demonstrated a significant effect of “Treatment” 
(F[1,490] = 64.10, p < 0.0001), a significant effect of “Block” (F[9,490] = 159.82, p < 
0.0001 ), and a significant ‘Tretament’ X ‘Block’ interaction (F[9,490] = 7.86, p = 
0.0001).  A separate analysis of performance within a block revealed aCSF-treated 
animals performed significantly better than SAP treated animals during blocks 4-7 of 
training.    
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Figure 1.  Effects of SAP-lesion of the MS on the number of days to reach criterion 
in the DMP T-maze task.   
Bar graph of days to reach criterion in the DMP T-maze task. Top of bar represents the mean 
number of days to reach criterion ± standard error of the mean.  Note that SAP-MS treated 
animals required significantly more days to reach criterion than the aCSF- treated controls.  * p < 
0.05 relative to the aCSF-treated control animals. 
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Figure 2.  Effects of SAP-lesion of the MS on the rate of acquisition in the DMP T-
maze task.  
Learning curves show the effects of SAP lesioning of MS on the rate of DMP acquisition.  Points 
represent the mean percentage correct for each treatment group during a 3 day period of training.  
By day 21 of training, all control animals had reached criterion, and only four of nine SAP treated 
animals had reached criterion.  By day 30 all animals had reached criterion.  Note that both 
groups showed improved rates of performance over time; however, during blocks 4–7 the rate of 
performance of the SAP treated animals was significantly impaired compared to the control 
animals.  ** p < 0.0001, * p < 0.05 for aCSF treated control animals relative to each of the SAP 
treated groups.   
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4.  Discussion: 
 
 The behavioral results show that SAP treated animals were significantly impaired 
in the acquisition of the DMP task.  Specifically SAP treated animals took significantly 
longer to reach criterion and improved at a slower rate compared to controls (Fig. 1, 2). 
The specific cognitive processes disrupted following SAP lesion of the MS still remain 
unknown.   
 The motor activity of the different treatment groups during the acclimation phase 
of the DMP T-maze task suggests that there is no change in the motor activity following 
the SAP infusion.  Both treatment groups could readily transverse the maze and obtain 
the reward pellets.  Furthermore, there was no difference in the ability of SAP treated 
animals to explore an open field as compared to aCSF treated controls.  This suggests that 
the decrease in the rate of acquisition and the increase in days to reach criterion was not 
influenced by the motor activity of the different treatment groups.    
 Several studies have reported limited to no effects of SAP lesion of the basal 
forebrain on tests of spatial working memory in rats.  Mild working memory deficits 
were reported using a delayed non-matching to sample radial arm maze following SAP 
lesion of the MS (189).  No deficits in memory recall were reported in rats that acquired a 
spatial paradigm followed by SAP lesioning of the MS and retesting (190).  Likewise, 
there was no reported effect of SAP lesion of the MS, NBM, or MS plus NBM on spatial 
working memory in the Morris water maze (179-181).  Moreover, Cahill and Baxter 
(191) reported facilitated acquisition of a discrimination task following SAP-lesions to 
the MS, suggesting no deficit in spatial working memory.  No significant performance 
differences were reported between SAP lesions of the MS or control rats when the 
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intertrial delay between the forced and open choice was increased in the DMP task once 
animals reached criterion (82,188).  Together, these findings suggest that any spatial 
working memory deficit produced by selective loss of the septal-hippocampal cholinergic 
neurons is mild at best, and not likely to account for the diminished acquisition of the 
DMP task following SAP lesion of the MS.                    
 Other reports suggest that cholinergic neurons of the basal forebrain are more 
important for attentional processes than working memory processes.  For example, 
several studies have reported significant deficits on tests of visual attention following 
SAP lesions of the NBM (192-194).  Cholinergic projections from the MS were less 
involved in visual attention processes (195), but may influence other attentional processes 
important in acquisition of a spatial task.   
 Rats have a natural tendency for spontaneous alternation, which affects 
performance on spatial alternation tasks (184, 185).  In a simple alternation task, many 
rats performed better than chance on the first day of acquisition (184, 185).  As a result, it 
is often difficult when using a simple alternation paradigm to assess the rate of 
acquisition and overall performance of the animals.  It was reported that infusions of SAP 
into the NBM of rats had no effect on the acquisition of a T-maze alternation task (196).  
Examination of the learning curves showed that the performance of control animals was 
near criterion, and that SAP lesioned animals performed better than chance at the 
beginning of training.  Employing a T-maze alternation task, therefore, would make any 
effect on learning difficult to assess.  By utilizing the DMP paradigm, the natural 
tendency of rats to alternate is opposed, thereby increasing the initial difficulty of the task 
and the sensitivity of the task to detect changes in task acquisition.  This was evident on 
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the first day of training, where both the control and SAP lesioned rats perform below 
chance (Fig. 2).  Following day 1 of training, the performance of all animals improved 
with control animals quickly surpassing the rate of acquisition for SAP lesioned rats.  The 
DMP paradigm provided a sensitive behavioral assay for revealing selective deficits in 
the septo-hippocampal cholinergic pathway, while the specific cognitive process 
underlying the decreased rate of acquisition remained unclear.   One of the most popular 
theories for the role of the hippocampus states that a map of the environment is built up 
in the hippocampus and serves to guide the animal within its environment (197).  
According to this theory, animals with hippocampal hypofunction are unable to use 
spatial strategies (based on a cognitive map), but can use either an orientation or guidance 
strategy, which are mediated by non-hippocampal structures.  A possible explanation for 
the decreased rate of acquisition could be a decrease ability to use a spatial strategy or 
greater reliance on another learning strategy.                                
 
 
C.  Effects of medial septum cholinergic lesions on learning strategies. 
 
1. Introduction 
 Recently, investigations utilizing the selective cholinergic immunotoxin 192-IgG 
Saporin (SAP) have found that lesioning cholinergic neurons of the MS has little or no 
effect on working memory in tests such as the Morris water maze (179, 180, 190).  
However, as documented in Experiment B this same lesion significantly delays 
acquisition of a DMP T-maze task.  Rats can utilize a number of different strategies to 
solve spatial tasks (for a review, see (27)).  For example, an animal may utilize a 
consistent directional body turn to navigate a maze using either egocentric or allocentric 
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cues, or a spatial strategy that relies on the location of extra maze visual cues (198-200).  
Evidence suggests that turning strategies rely primarily on striatal circuits whereas spatial 
strategies rely more on hippocampal circuits (198, 200-202).  As an example, when the 
dorsal hippocampus was inactivated via an infusion of lidocaine, use of a place strategy 
was inhibited (199).  Conversely, following stimulation of the dorsal hippocampus with 
glutamate, rodents preferentially chose a place learning strategy (199).  Therefore, 
another mechanism by which MS cholinergic lesions could affect DMP acquisition 
independent of working memory is by affecting the use and/or preservation of a place or 
response strategy.  The purpose of this study was to test the hypothesis that MS 
cholinergic lesions impair DMP acquisition in male rats by causing alterations in the 
adoption and/or preservation of the learning strategies used within the DMP task.  We 
predicted that SAP treated animals will use a persistent turning strategy for significantly 
more days, influencing the number of days the animal needs to reach criterion in the 
DMP task and the rate of acquisition for the task. 
 
2. Methods 
 Immunolesioning of the cholinergic neurons of the MS with SAP was performed 
as documented in Experiment A.  Following behavioral testing ChAT activity in the 
hippocampus and frontal cortex was determined for each animal as described in 
Experiment A.  SAP treated animals that did not show selective decrease in ChAT 
activity within the hippocampus were eliminated from the study. 
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i.  Post-criterion Spatial Manipulation: 
 Fourteen days after surgery for SAP infusion, animals were food deprived to 85% 
of their normal body weight and then acclimated to the T-maze as described in 
Experiment B.  Acquisition of the DMP task, described in Experiment B, continued until 
two stages of learning were established.  One group of animals (criterion performance) 
received eight trial pairs per day until the animals acquired the DMP paradigm, defined 
as 15 correct choices out of 16 consecutive trial pairs, while another group (response like 
performance) received training until 15 out of 16 entries into the same goal arm was 
observed.  Once either criterion was reached, spatial manipulation was introduced into 
the testing procedure.  During a morning session animals were run as described for the 
DMP task.  During the afternoon session, animals completed the forced choice, but 
before the second open choice of the trial pair, the maze was rotated 180º.  The animals 
were then placed in the start box and allowed to complete the second part of the trial pair.  
Use of a response like strategy was defined as entering the same physical goal arm in at 
least 7 out of 8 trials per day.  A place strategy was defined as returning to the goal arm 
located in the same location within the testing environment 7 out of 8 times. 
 
ii.  Statistical Analysis: 
 During the course of DMP training it was observed that throughout early stages of 
training, many animals adopt a turning strategy whereby they consistently turned to the 
right or left goal arm of the maze.  To quantify this observation, we counted the total 
number of days the animals utilized the strategy during the testing process.  Any animal 
that entered 7 out of 8 times into the same goal arm was defined as using a turning 
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strategy.  A student T-test was used to analyze the number of animals that adopted this 
strategy and also the number of days that an animal utilized the strategy.  To evaluate the 
contribution that the turning strategy had on the number of days to reach criterion, the 
duration of the turning strategy was subtracted from the overall days to criterion from 
each animal and analyzed with a student T-test.  Effects of rotating the maze 180° 
between the open and forced chioce were analyzed by ANOVA comparing the 
performance during a normal morning session with performance in an afternoon session 
when the maze was rotated.  Performance and days to criterion were analyzed as 
parametric data.  
 One goal of the research was to test the predictions about the relationship between 
cholinergic activity in different brain regions and the different learning strategies adopted 
by each treatment group.  ChAT activity was used to measure the cholinergic activity 
with in the hippocampus and frontal cortex.  To compare the number of days with a 
turning strategy and ChAT activity, a scatter plot was developed and analyzed utilizing a 
Spearman’s Rho correlation between groups and within groups.  All analyses were 
performed using GraphPad Prism 3.0. 
 
3.  Results 
 Animals appeared to adopt different learning strategies at different times during 
training of the DMP task.   To determine changes in learning strategies, a probe trial was 
introduced once animals reached two different stages of learning.  We observed that 
during the early stages it appeared that animals adopted a turning strategy, where animals 
entered the same arm during the open trial no matter which arm they entered in the forced 
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trial.  Therefore, the criterion for the first stage of learning that was examined was 
defined as 15/16 turns into the same arm of the T-maze as during the open trial.  Prior 
observations have shown that animals reach this criterion early in training (days 3-6).  
The second stage of learning was followed by additional training when an animal reached 
the DMP criterion, defined as 15/16 correct choices (days 16-24).  After reaching either 
criterion, each rat received a probe trial over three consecutive days during which the 
maze was rotated 180° (relative to the extra-maze cues) between the forced and open 
trials.  Animals using extra-maze cues would enter the arm in the same location of the 
room as previously visited.  This would be the opposite arm visited during the forced 
trial, thus an incorrect choice.  Animals relying on internal cues would be expected to 
enter the same physical arm of the T-maze entered during the forced trial no matter the 
orientation of the maze in the testing room: a correct choice.  
 A probe trial introduced during the earlier stage of learning had no significant 
effect on the performance (Fig. 3A–3B) of either aCSF-treated controls or SAP treated 
animals.  During a morning session of normal DMP training, aCSF treated animals 
displayed an average performance of 47.40 ± 1.06% correct, compared to the probe trial 
when animals displayed an average performance of 50.00 ± 1.51% correct.  SAP treated 
animals also displayed similar behavior with an average performance of 48.75 ± 0.86% 
correct during normal DMP training and an average performance of 49.38 ± 2.31% 
correct during the probe trial.  
 Since animals seemed to adopt a turning strategy at this early stage in training, the 
number of times an animal entered a single arm of the T-maze during the open trial was 
also examined.  The probe trial introduced during this stage of learning had no significant 
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effect on the established turning strategy for either the aCSF treated or SAP treated 
animals (Fig. 4A–4B).  During the morning session of normal DMP training, the aCSF 
treated animals averaged 7.83 ± 0.08 turns into a single goal arm of the T-maze during 
the open trial, compared to the probe trial when these same animals averaged 7.46 ± 0.19 
turns into the same arm.  SAP treated animals displayed similar behavior.  During a 
normal training session SAP treated animals averaged 7.86 ± 0.14 turns into a single arm 
during the open trial, compared to the probe trial when these same animals averaged 7.71 
± 0.28 turns into the same arm.  The performance and entry patterns suggest that during 
this stage of learning, rotating the maze had no effect on arm choice in each of the 
treatment groups.  This result indicates that during the early stages of learning, neither 
treatment group used extra-maze cues to a significant degree to navigate the maze. 
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Figure 3A - 3B.  Effects of rotating the T-maze on performance of animals using 
persistent turning strategy.  
The performance of aCSF treated control animals (n=8) and SAP treated animals (n=6) during a 
normal trial pair (days 1a – 3a) and the probe trial (days 1b – 3b) over three consecutive days.  
Performance during the early stages of training when animals exhibited a turning strategy as 
defined by 15/16 turns to the same arm.  The bars represent the mean percentage correct ± s.e.m.  
Note that introducing a probe trail had no significant effect on performance of either aCSF treated 
controls or SAP treated animals.  
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Figure 4A – 4B.  Effects of rotating the T-maze on entry patterns of animals using a 
persistent turning strategy. 
Scatter plots showing entry patterns for aCSF treated control animals (n=8) and SAP treated 
animals (n=6) during a normal trial pair (day1a-3a) and the probe trial (day1b-3b) over three 
consecutive days.  Entry patterns summarized is during the early stages of training when animals 
exhibited a turning strategy defined by 15/16 turns to the same arm.  The line in the middle 
represents the mean ± s.e.m.  Note that introducing a probe trail had no significant effect on 
entries into a single arm of the T-maze for either aCSF treated controls or SAP treated animals. 
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 A probe trial introduced following additional DMP training had a significant 
effect on the performance for both aCSF treated and SAP treated animals that had 
reached criterion in the DMP task (Fig. 5A–5B).  During three consecutive days of the 
probe trial, the average performance was 53.13 ± 3.63% for aCSF treated controls and 
63.02 ± 2.76% for SAP treated animals.  These values differed significantly from 
performance during the normal training session (93.23 ± 2.13% for aCSF treated 
controls; 94.27 ± 1.50% for SAP treated animals; p < 0.001 for all days).  Changes in 
performance indicated that following additional training, rotating the maze disrupted arm 
choice for both treatment groups.  This result indicated that for the rats to solve the T-
maze DMP paradigm they relied on extra-maze cues when making an arm choice.     
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Figure 5A – 5B.  Effects of rotating the T-maze on animals that have reached 
criterion following extensive training.   
The performance of aCSF treated control animals (n=8) and SAP treated animals (n=8) during a 
normal trial pair (days 1a – 3a) and the probe trial (days 1b – 3b) over three consecutive days.  
Performance summarized is following extensive training when animals have solved the maze and 
chose 15/16 correct.  The bars represent the mean percentage correct ± s.e.m.  Note that 
introducing a probe trail significantly decreased the performance of both aCSF treated controls 
and SAP treated animals.  *** p < 0.001 relative to the normal trial pair (days 1a – 3a).  
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 As mentioned above, we observed that during early stages of training many of the 
animals adopted a turning strategy.  Of the eight aCSF treated control animals, six 
developed a turning strategy (75%), defined as 15/16 turns to the same goal arm.  All 
nine SAP treated animals adopted the turning strategy (100%).  There was no significant 
difference in the number of days before each of the groups of animals adopted the turning 
strategy.  aCSF treated controls took an average of 4.5 ± 1.6 days to adopt this learning 
strategy while SAP treated animals took an average of 4.7 ± 0.9 days.  The number of 
days that animals engaged in the turning strategy was significantly greater for rats with 
SAP lesion of the MS (Fig. 6).  SAP treated animals engaged in a turning strategy for 
14.33 ± 1.81 days while aCSF treated controls engaged in this strategy for 6.63 ± 1.71 
days. 
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Figure 6.  Number of days animals were engaged in a persistent turning strategy 
during DMP training. 
The number of days rats displayed a turning strategy during DMP T-maze training.  Line 
in the middle represents the mean ± s.e.m.  Note that SAP treated animals adopted a 
turning strategy for more days when compared to controls.  ** p < 0.01 relative to the 
aCSF treated controls.  
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 To determine whether the percentage of animals that adopted the turning strategy 
had any significant effect on the analysis of the number of days animals engaged in the 
turning strategy, those animals that never adopted a turning strategy were excluded.  
After excluding these animals, there was still a significant difference between SAP 
treated animals and aCSF treated controls (Fig. 7), suggesting that at least some of the 
difference was due to an increased utilization of the turning strategy following SAP 
lesioning of the MS. 
 To determine whether the differences in the number of days rats were engaged in 
a turning strategy was enough to explain the effects of treatment differences on 
acquisition of the DMP task, the days using the turning strategy were subtracted from 
days required to reach criterion (Fig. 8).  Once the days using a turning strategy were 
subtracted from days to criterion, no significant effect on days to criterion was seen with 
SAP lesion of the MS (p = 0.49).  This finding indicated that a significant portion of the 
effect SAP lesion had on days to criterion was due to the number of days SAP-MS 
animals were engaged in a turning strategy.             
 Next, correlations between duration of the turning strategy and ChAT activity in 
different brain regions were examined (Fig. 9A – 9B).  Spearmen correlation of ChAT 
activity within the hippocampus revealed a significant negative correlation (p < 0.05),   
indicating that as ChAT activity within the hippocampus increased, the number of days 
the animals engaged in a turning strategy decreased.  No relationship was revealed when 
comparing ChAT activity in the frontal cortex and the number of days animals utilized a 
turning strategy.  The relationship between ChAT activity in the hippocampus and 
turning strategy was further analyzed by Spearmen correlation within each treatment 
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group.  Within each treatment group (aCSF-controls, SAP-MS) there was no significant 
relationship between ChAT activity of the hippocampus and turning strategy. 
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Figure 7.  Number of days animals were engaged in a persistent turning strategy 
excluding those animals which never adopted the learning strategy. 
The number of days rats displayed a turning strategy during DMP T-maze training, excluding 
those animals that never adopted the strategy.  The line in the middle represents the mean ± 
s.e.m.  Note that SAP treated animals still adopted a turning strategy for more days (14.33 ± 1.81) 
when compared to controls (8.83 ± 1.24).  * p < 0.05 relative to the aCSF treated controls. 
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Figure 8.  Effect of SAP-lesion of the MS on the number of days to reach criterion in 
the DMP-task excluding days animals were engaged in a persistent turning strategy. 
Bar graph represents the days to reach criterion in the DMP task.  Top of bar is the mean 
± sem.  Note that SAP-MS treated animals no longer required significantly more days to 
reach criterion when compared to controls [ p=0.48]. 
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Figure 9A – 9B.  Correlation of ChAT activity with the number of days animals 
adopted a persistent turning strategy. 
The correlation of ChAT activity in the hippocampus (panel A) and frontal cortex (panel 
B) with the number of days animals adopt a turning strategy.  
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4.  Discussion: 
 
 Examining learning curves and response patterns (Fig. 2) suggests that the 
acquisition deficit in the DMP task following SAP lesion of the MS most likely was 
related to the strategies adopted during training.  At the start of training, all groups 
performed below chance, reflecting the rats’ natural tendency for spontaneous alternation 
(not revisiting a prior location), but after 6 to 9 days of training the rodents reached 
chance performance.  This period of training coincided with the period of training when 
most animals adopted a persistent turning strategy, always entering either the left or right 
goal arm during the open choice trial.  These findings are similar to observations made by 
Pych et al. who noted that some rats tested on a spontaneous alternation task adopted a 
persistent turning strategy (197).  In the DMP task, use of a persistent turning strategy 
resulted in enhanced performance early, but with further training the rodents’ 
performance maintained 50% correct.  To further improve performance and ultimately 
reach criterion, the behavioral patterns needed to change, adopting an alternative strategy.  
Therefore, the number of days to reach criterion was a function of when the animal 
adopted a persistent turning strategy, the number of days that the animal uses this 
strategy, and the ability of the animal to deviate from this strategy and adopt a different 
strategy.   
 Analysis of the data showed that SAP lesion of the MS had no effect on the 
likelihood that an animal would adopt a turning strategy (defined as 7/8 turns to the same 
goal arm) during training of the DMP paradigm.  However, SAP lesion increased the 
number of days that rats utilized the persistent turning strategy before switching to the 
more successful DMP strategy to reach criterion.   
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When the number of days rats used a turning strategy was subtracted from 
number of days rats took to reach criterion, no significant effect of SAP lesion was 
detected.  This result suggests that the effect of SAP lesion on DMP acquisition can be 
fully explained by the change in response pattern; extended use of a persistent turning 
strategy; and a delay in changing to the DMP strategy during training.  This result also 
suggests that SAP lesion of the MS has a greater impact on cognitive flexibility, as 
opposed to spatial working memory.   
 It was clear that both treatment groups adopted a persistent turning strategy early 
during training, but what was not clear was whether both groups utilized the same cues to 
drive this strategy.  Once animals adopted the turning strategy the introduction of the 
probe trial indicated that rotating the maze between forced and open choices failed to 
disrupt arm choice.  This result demonstrated that when rotating the maze, animals still 
persisted in turning consistently to left or right goal arm.  This indicates that neither 
treatment groups utilized extramaze cues to navigate to the goal arm; but adopted an 
egocentric (response) strategy that was manifested as persistent turning early in 
acquisition training.  
 It was also clear that nearly all animals adopted the more successful DMP 
strategy, because with extensive training most animals reached criterion.  This raised the 
question of whether both treatment groups eventually would adopt the same strategy to 
reach criterion (15/16 correct choices).  Examining the results of the probe trial after the 
rats reached criterion indicated that rotating the maze disrupted performance to chance 
levels.  Furthermore, examining the response patterns after rotating the maze indicated 
that certain animals from each treatment group readopt a persistent turning strategy, 
79 
 
while other animals appeared to select goal arms at random.  One of three possibilities 
was concluded by the time rats reached criterion:  1.) A significant number of animals in 
each treatment group used extramaze cues to select the correct goal arm. Use of 
extramaze cues is consistent with an allocentric strategy.  Rotating the maze made these 
animals become confused and they choose arms at random.  2.) Each animal in each 
group was equally likely to use a persistent turning strategy or extramaze cues to make a 
selection during the choice phase of learning.  3.) Half of the animals in each group were 
strongly inclined to use extramaze cues to make their choice and half were strongly 
inclined to use a persistent turning strategy.      
 Correlation analysis of ChAT activity vs. days to criterion revealed a negative 
correlation between the number of days with a turning strategy and the degree of 
cholinergic activity in the hippocampi for both treatment groups.  Note that a negative 
correlation indicates that a decrease in ChAT activity was associated with an increase in 
the number of days animals used a turning strategy.  This same correlation could not be 
made within each treatment group.  This finding may suggest that when cholinergic 
afferents to the hippocampus are destroyed, there is a causal relationship between the 
degree of cholinergic impairment and the delay in shift to an allocentric strategy.  This 
could also suggest that when the cholinergic inputs to one structure are compromised, 
remaining intact structures may become more influential in determining the navigational 
strategy used.   
 It is well accepted that different neuronal circuits underlie different types of 
learning strategies, and that the activity of specific cholinergic projections can reflect the 
use of different strategies (for review see 65).  It is also well accepted that rodents can use 
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a variety of learning strategies to acquire T-maze tasks, and that the strategy can change 
throughout the course of training (203).  Rats trained to approach a bated arm in a cross 
maze initially used a place strategy, but later shifted to a response strategy, indicating that 
with extensive training a shift in learning strategies can control the animals’ behavior 
(200).  This study also showed that inactivation of the hippocampus with lidocaine 
selectively interfered with a rodents’ ability to adopt a place strategy, while inactivation 
of the caudate nucleus selectively interfered with the adoption of a response strategy.  
These results suggest that the hippocampus and caudate nucleus are differentially 
promoting two distinct navigational strategies in the T-maze. 
    In addition, studies from Gold and colleagues have examined the release of 
acetylcholine in the hippocampus and other structures as a marker for the involvement of 
different neuronal systems in specific behavioral responses or cognitive processes.  For 
example, the ratio of acetylcholine released from the hippocampus and caudate nucleus 
can accurately reflect the use of place and response strategies used during training (204).  
When rats were trained on a plus maze that could be learned using either a response or 
place strategy, the rats that used the response strategy displayed a lower ratio of 
acetylcholine release in the hippocampus/striatum than rats that used the place strategy 
(204).  Furthermore, Gold et al. (67) showed that in the cross maze the cholinergic 
hippocampal system was engaged first before the striatum was activated, and that the 
hippocampus was important for place learning.  Later in training, although the 
hippocampus remained activated, the striatum was also activated in a manner that 
enabled the use of a response strategy to solve the maze.  These results suggest that the 
behavioral flexibility needed to change learning strategies was associated with 
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cholinergic activity of the dorsal striatum as opposed to cholinergic activity of cortical 
structures.  Further studies are needed to determine whether cholinergic activity in other 
neuronal systems can affect the utilization of different nagivational strategies in the DMP 
paradigm.   
In another study, rats tested on a food-reward spontaneous alternation task 
initially used a spatial working memory strategy, but later shifted to a persistent turning 
strategy (197).  Again, as rats adopted the persistent turning strategy, the ratio of 
hippocampal/striatal ACh released steadily decreased.  Recently, Pych et al. showed that 
ACh release was greater in the striatum during training on a response food-reward task as 
compared to the same place food-reward task (67).  The levels of ACh increased in the 
place and response tasks when extramaze cues were available.  When these cues were 
minimized the levels of ACh were significantly lower during training with a response 
task.  This finding demonstrated a strong relationship between the ratios of cholinergic 
activity in different neuronal systems and the adoption of different learning strategies.  
These results also provide a possible explanation for the extended reliance on the 
persistent turning- response strategy following septo-hippocampal cholinergic lesions.   
 In summary, the data show that SAP lesion of the MS impaired acquisition of the 
DMP task, and that this effect was primarily due to a delayed shift in navigational 
strategy during training.  Specifically, septo-hippocampal cholinergic lesions appeared to 
impair the ability of animals to adopt an allocentric place strategy needed to reach 
criterion.   
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D.  Effects of DU-14 treatment on spatial acquisition of medial septum cholinergic 
lesioned rats. 
 
1. Introduction 
 There is now good evidence that the metabolism of DHEA and its sulfated form 
occurs bi-directionally within the CNS, with DHEAS being desulfated via the enzyme 
steroid sulfatase (108).  DU-14 is a potent non-estrogenic irreversible inhibitor of steroid 
sulfatase.  A single dose of DU-14 (30 mg/kg) was able to inhibit 95.2% of the steroid 
sulfatase activity within the liver (116).  Furthermore, this treatment was able to 
significantly lower steroid sulfatase activity within the brain but at a substantially lower 
rate (14.8% reduction in activity) (116).  Chronic treatments with DU-14 (30 mg/kg for 
15 days i.p.) in rodents increased plasma concentrations of DHEAS, while decreasing 
plasma DHEA (113).  Furthermore, this same treatment increased whole brain levels of 
DHEAS.   
 The administration of DU-14 (30 mg/kg, i.p.) has been shown to increase 
hippocampal ACh release, a result which supports the findings that increased DHEAS 
levels in the brain augment the levels of ACh within the hippocampus (157).  
Additionally, chronic pretreatment with DU-14 (30 mg/kg for 15 days i.p.) attenuated 
scopolamine induced spatial memory impairment in the passive avoidance paradigm and 
Morris water maze (116, 158).  In the Morris water maze not only did DU-14 reverse the 
scopolamine induced amnesia, but enhanced the performance of control animals (116).   
In agreement with the GABA antagonistic action of DHEAS, these findings suggested 
that DHEAS rather than DHEA was responsible for memory enhancement.  Since all of 
these experiments administered the steroid sulfatase inhibitor through an i.p. route, it 
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remains unclear whether the observed effects were caused by actions of the inhibitor at 
the peripheral or central level.   
 We hypothesized that DU-14 will attenuate the cognitive deficits associated with 
lesion of septal-hippocampal cholinergic projections.  DU-14 is one possible treatment 
which could reverse impairments in the DMP task associated with SAP lesioning of the 
MS.  Studies have shown that DU-14 does, in fact, increase DHEAS in both plasma and 
whole brain, elevates hippocampal ACh, and enhances passive avoidance retention as 
well as performance in the Morris water maze (113, 197, 205).  Whether the memory-
enhancing effects associated with DU-14 require an intact septal-hippocampal tract or if 
DU-14 can improve spatial acquisition in SAP lesioned animals remains unknown.  We 
predict that chronic treatments of DU-14 will improve performance of both SAP treated 
and aCSF treated control animals in the DMP T-maze task.  Where the cognitive 
enhancing effects associated with DU-14 are due specifically to changes in Ach release in 
the hippocampus and cortex is currently unknown.  One possibility is that DU-14 may 
also affect non-cholinergic systems in ways which can compensate for the loss of 
muscarinic cholinergic activity. If so, then steroid sulfatase inhibitors could potentially 
provide effective agents for the treatment of cognitive dysfunctions associated with a loss 
of basal forebrain cholinergic neurons such as in AD.  This study will help determine the 
mechanisms by which steroid sulfatase inhibitors enhance learning and memory 
processes, and may ultimately lead to the development of a new class of therapeutic 
agents for the treatment of cognitive decline associated with aging and AD.   
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2. Methods 
 Immunolesioning of the cholinergic neurons of the MS with SAP was performed 
as documented in Experiment A.  Acclimation and acquisition of the DMP T-maze task 
was performed as documented in Experiment B.  Following behavioral testing ChAT 
activity in the hippocampus and frontal cortex was determined for each animal as 
described in Experiment A.  SAP treated animals that did not show selective decrease in 
ChAT activity within the hippocampus were eliminated from the study. 
 
i.  (P-o-sulfamoyl)-N-tetradeconoyl tyramine (DU-14) Treatment: 
 Fourteen days after SAP or aCSF infusion, the animals were randomly separated 
into DU-14 treatment group and controls.  DU-14 was suspended in corn oil.  DU-14 (30 
mg/kg, i.p.) or vehicle (oil) was administered, via an IP injection, 4 hours following the 
testing procedure.  This treatment regiment was continued until the animal met a criterion 
of 15 correct choices out of 16 consecutive trial pairs.  So that introduction of an aversive 
stimulus would not interfere with testing, administration of DU-14 4 hours following 
testing was chosen.  The concentration and route of administration of DU-14 (30 mg/kg, 
i.p.) used in this study has been shown to increase DHEAS in both plasma and whole 
brain, elevates hippocampal ACh, and enhances passive avoidance retention as well as 
performance in the Morris water maze (113, 197, 205).   
 
ii. Statistical Analysis: 
 Days to criterion were analyzed using a parametric one-way ANOVA with 
Newman-Keuls post hoc test. To compare treatment effects during different stages of 
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acquisition, performance data was blocked into 3-day periods of training.  After an 
animal had reached criterion a value of 93.75% (15/16) was recorded for performance on 
subsequent days.  Performance during acquisition testing was analyzed using two-way 
ANOVA for overall effects of block and treatment and one-way ANOVA with Newman-
Keuls post hoc test for treatment effects within blocks.   
 During the course of DMP training it was observed that throughout early stages of 
training, many animals adopt a turning strategy whereby they consistently turned to the 
right or left goal arm of the maze.  To quantify this observation, we counted the total 
number of days the animals utilized the strategy during the testing process.  Any animal 
that entered 7 out of 8 times into the same goal arm was defined as using a turning 
strategy.  A one-way ANOVA with Newman-Keuls post hoc test was used to analyze the 
number of animals that adopted this strategy and also the number of days that an animal 
utilized the strategy.  Both the rate of performance and days to reach criterion in the DMP 
t-maze task was determined to be parametric.  All analyses were performed using 
GraphPad Prism 3.0. 
     
3.  Results 
 Of the original 56 animals, all but three animals failed to reach criterion on the 
delayed matching to position (DMP) task or displayed a preference for one goal arm of 
the T-maze (side bias) and were excluded from the study.  Two of the three animals were 
aCSF-vehicle treated control animals while the other was a SAP-MS DU-14 treated 
animal.  Analysis of the remaining animals (12 aCSF-vehicle, 14 aCSF-DU-14,  14 SAP-
MS vehicle, and 13 SAP-MS DU-14 treated animals) indicated that SAP treated animals 
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required more days to reach criterion and treatments with DU-14 further increased the 
number of days required for the animals to reach criterion (Fig. 10).  Analysis of days to 
criterion by a Newman Keuls one-way ANOVA found a significant effect of DU-14 
treatment in SAP-MS animals (p < 0.05), indicating that SAP-MS vehicle treated animals 
differed significantly from the SAP-MS DU-14 treated animals with SAP-MS lesioned 
animals taking a significantly longer time to complete the maze compared to treatment 
controls.  Furthermore, there was a significant effect of SAP lesioning in both treatment 
groups (p<0.05).  aCSF vehicle treated animals took an average of 14.33 ± 3.2 days while 
the SAP-MS vehicle treated animals took an average of 17.86 ± 3.527 to complete the 
DMP task.  Treatment with DU-14 significantly increased the number of days to criterion 
for SAP-MS animals while having no significant impact on the days to criterion for aCSF 
treated controls.  SAP-MS vehicle treated animals took an average of 17.86 ± 3.527 to 
complete the DMP task while treatment with DU-14 increased days to criterion to an 
average of 21.15 ± 4.451.   
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Figure 10.  Effects of DU-14 treatment on the number of days to reach criterion in 
the DMP T-maze task.   
Bar graph representing the effect of DU-14 treatment on spatial acquisition of MS cholinergic 
lesioned rats.  Top of bar represents the mean number of days to reach criterion ± sem.   DU-14 
treated SAP-MS animals required significantly more days to reach criterion than the SAP vehicle 
treated animals.  DU-14 had no effect on days to criterion of aCSF control animals. a: p < 0.05 
relative to the aCSF-vehicle treated animals.  b: p < 0.01 relative to the aCSF-DU14 treated 
animals.  c: p < 0.05 relative to SAP-MS vehicle treated animals. 
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 Examination of the learning curves (Fig. 11) show that all animals performed at 
similar, below chance, levels at the start of DMP training.  SAP-MS vehicle treated 
animals improved at a slower rate during training when compared to aCSF vehicle treated 
controls.  SAP-MS DU-14 treated animals improved at the slowest rate.  By day 21 of 
training, all aCSF vehicle treated animals and all but one aCSF DU-14 treated had 
reached criterion.  On the other hand, only six of 13 SAP-MS DU-14 treated animals had 
reached criterion.  By day thirty all animals reached criterion.  Analysis of the learning 
curves by two-way ANOVA demonstrated a significant effect of “Treatment” (F[27,88] = 
6.88, p < 0.0001), a significant effect of “Block” (F[9,5425] = 425.90, p < 0.0001 ), and a 
significant ‘Treatment’ X ‘Block’ interaction (F[27,88] = 6.88, p < 0.0001).  A separate 
analysis of performance within block revealed aCSF vehicle treated animals performed 
significantly better than SAP vehicle treated animals during blocks 4 and 5 of training.  
aCSF DU-14 treated animals performed significantly better during blocks 3 and 4 when 
compared to aCSF vehicle treated animals.  SAP-MS vehicle animals performed 
significantly better during blocks 4 and 6 when compared to SAP-MS DU-14 treated 
animals. 
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Figure 11.  Effects of DU-14 treatment on the rate of acquisition in the DMP T-maze 
task.   
The effects of DU-14 treatment on the rate of DMP acquisition for SAP-MS lesioned rats.  Points 
represent the mean percentage correct for each treatment group during a 3 day period of training.  
Note that all groups showed improved performance over time; however during blocks 4 and 6 the 
performance of the SAP-MS DU-14 treated animals was significantly worse than the 
corresponding SAP-MS vehicle.  Also during blocks 3 and 4 aCSF vehicle treated animals 
performed significantly worse than aCSF DU-14 treated animals.  a: p < 0.005 for aCSF vehicle 
treated animals relative to SAP-MS vehicle treated animals.  b: p < 0.005 for aCSF DU-14 treated 
animals relative to SAP-MS DU-14 treated animals.  c: p < 0.005 for SAP-MS vehicle treated 
animals relative to SAP-MS DU-14 treated animals.  d: p < 0.005 for aCSF vehicle treated 
animals relative to aCSF DU-14 treated animals. 
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Figure 12:  Effects that the daily injections of DU-14 had on the utilization of a 
persistent turning strategy. 
The number of days rats displayed a turning strategy during DMP T-maze training.  The top of 
the bar represents the mean number of days using a turning strategy ± s.e.m.  Note that SAP-MS 
vehicle treated animals adopted a turning strategy for more days compared to aCSF vehicle 
treated controls.  Also note that there was no significance difference between aCSF DU-14 and 
aCSF vehicle.  Furthermore SAP-MS DU-14 animals did not utilize a turning strategy for 
significantly more days when compared to vehicle treated SAP-MS animals.   a.  p < 0.001 
relative to the aCSF vehicle and DU-14 treated controls.  b. p<0.001 relative to aCSF vehicle and 
DU-14 treated animals. 
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 As mentioned above, we observed that during early stages of training many of the 
animals adopted a turning strategy.  There was no significant difference in the number of 
animals in each treatment group which adopted the persistent turning strategy.  
Furthermore, there was no significant difference in the number of days before each of the 
treatment groups adopted the turning strategy.  The number of days that animals engaged 
in the turning strategy was significantly (p<0.001) greater for rats with SAP lesions (Fig. 
12).  SAP-MS vehicle treated animals engaged in a turning strategy for 14.50 ± 1.18 days 
while aCSF vehicle treated controls engaged in this strategy for 8.33 ± .80 days.  SAP-
MS DU-14 treated animals engaged in a turning strategy for 14.08 ± 1.25 days while 
aCSF DU-14 treated animals engaged in this strategy for 7.35 ± 0.71 days.  However, 
there was no significant difference in the number of days SAP-MS or aCSF animals used 
the turning strategy following DU-14 treated.  To determine whether the percentage of 
animals that adopted the turning strategy had any significant effect on the analysis of the 
number of days animals engaged in the turning strategy, those animals that never adopted 
a turning strategy were excluded.  After excluding these animals, there was still no 
significant difference in the number of days SAP treated animals and aCSF treated 
controls used the turning strategy following DU-14 treatment.  This suggests that the 
difference in days to criterion between SAP-MS vehicle and SAP-MS DU-14 can not be 
explained by an increased utilization of the turning strategy following DU-14 treatment. 
 
 
4.  Discussion 
 
 Previous investigations found that in addition to decreasing scopolamine induced 
impairment in the Morris water maze, DU-14 (30 mg/kg i.p.) was able to enhanced 
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performance in control animals (152).  The mechanism of action for the enhanced 
cognitive function associated with steroid sulfatase inhibitors may be due to an increase 
in sulfated neurosteroids such as DHEAS and pregnenolone sulfate (PS) (113, 205).  
DHEAS and PS are allosteric antagonists of the GABAa receptor.  Since GABAergic 
neurons maintain an inhibitory tone on cholinergic neurons, DHEAS may disinhibit 
cholinergic firing resulting in enhanced activation of central muscarinic and nicotinic 
receptors.  Enhance activation of these receptors especially in the hippocampus could 
facilitate spatial learning and memory.  Another possible mechanism for the effect of 
DU-14 on memory could be through increased hippocampal Ach release (205). 
 Examination of the ability of DU-14 to attenuate impairment in the rate 
acquisition of the DMP task following SAP-MS lesions demonstrated that DU-14 
treatment further impaired acquisition for the SAP-MS treated rodents.  Specifically, 
lesioned rats that received DU-14 had an increase in the number of days to reach 
criterion.  This was a result of decreased performance during blocks 4 and 6 when 
compared to control treated SAP-MS lesioned animals.  These findings opposed the 
initial hypothesis, that chronic pretreatment with DU-14 would improve acquisition of the 
DMP paradigm for animals with SAP lesion of the MS.  One possible explanation for this 
result may be that GABAergic neurons play an important role in cognition aside from 
modulating cholinergic tone (206).  Decreased acquisition of the DMP task following 
SAP lesion of the MS may be further impaired by the loss of GABAergic 
neurotransmission via the physiologic antagonistic properties of DU-14.  DU-14 may be 
able to reverse scopolamine induced amnesia by increasing the cholinergic tone within 
the hippocampus.  Increased Ach release would then compete with scopolamine for 
93 
 
binding sites on muscarinic receptors.  However, unlike scopolamine induced amnesia, 
SAP lesion of the MS permanently destroys cholinergic afferents of the hippocampus.  
Therefore, with SAP lesioned animals, treatments with DU-14 may be unable to increase 
cholinergic activity within the hippocampus, resulting in no beneficial effect on memory.   
DU-14 treatment could increase Ach released in other neuronal systems involved 
in different learning strategies.  As stated above, Gold et al. (67) showed that relative 
levels of Ach in the hippocampus and striatum were associated with different learning 
strategies.  DU-14 treatment in SAP lesioned animals could increase acetylcholine levels 
in the striatum while hippocampal levels remained low, resulting in an ACh ratio 
favorable toward an egocentric response strategy.  This seems unlikely since there was no 
significant difference in the number of days DU-14 treated SAP-MS lesioned rats utilized 
the persistent turning strategy when compared to control treated SAP-MS rats. 
Another possible reason for the diminished performance of SAP-MS animals 
following DU-14 treatment may be changes in the theta rhythms in the hippocampus. 
Theta rhythms are one of several characteristic electroencephalogram waveforms 
associated with various states of sleep and wakefulness. Theta rhythms have been 
implicated in spatial navigation and some forms of learning and memory, especially those 
associated with the temporal lobes and the hippocampus (207).  Theta rhythm activity is 
also manifested during certain short-term memory tasks (208).  Studies suggest that these 
waves reflect the readiness of the hippocampus to process incoming signals (209).  
Furthermore, theta oscillations have been correlated to different voluntary behaviors 
(exploration, spatial navigation, etc.), suggesting that the theta oscillations may reflect the 
integration of sensory information with motor output (210, 211).  Treatments with DU-14 
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may alter theta oscillations and therefore diminish the ability to integrate the sensory 
information from the DMP task with the motor output.  SAP-MS animals treated with 
DU-14 may have a diminished ability to use the extra-maze cues to guide their behavior 
resulting in diminished rate of acquisition of the DMP task and increased days to 
criterion. 
In summary, the results suggest that the cognitive enhancing and anti-amnestic 
effects of DU-14 relay some what on an intact cholinergic afferent to the hippocampus.  
Furthermore, this may suggest that the cognitive enhancing and anti-amnestic effects of 
DU-14 are due to its ability to increase concentration ACh within the hippocampus.  
Since neither plasma nor whole brain concentrations of DHEAS were examined we 
cannot correlate findings to DHEAS levels.  Prior studies have found that acute 
administration of DHEAS increase the release of ACh in the rat hippocampus, with 
corresponding enhancement of passive avoidance retention.  It has yet to be determined if 
acute administration of DHEAS alone will improve spatial acquisition of SAP-MS 
lesioned rats. 
 
E.  Effects of DHEAS treatment on spatial acquisition of medial septum cholinergic 
lesioned rats. 
 
1. Introduction 
 DHEA and its sulfated ester DHEAS have gained significant interest in the field 
of neuroscience due to two findings:  a strong age associated decline of the steroid in 
humans and the demonstration of DHEA(S) metabolism and action in the rodent brain.    
DHEA(S) concentrations in the rodent brain far exceed peripheral concentrations and are 
independent of adrenal synthesis (108, 109).   
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 Flood et al. were the first to show the memory-enhancing effects of DHEA and 
DHEAS, in both young (120-122) and old (123) mice using a foot shock paradigm.  In 
their extensive studies, multiple routes of administration (i.c.v., s.c., oral) were utilized, 
all leading to an inverted U-shaped dose response curve for memory-enhancing effects.  
Melchior and Ritzmann (124) demonstrated that when administered i.p., both DHEA and 
DHEAS enhanced short-term working memory as assessed with a T-maze paradigm.  
Again, an inverted U-shaped dose response curve was observed.  Another group of 
experiments demonstrated that DHEAS enhanced memory when given before or directly 
after training, but not when administered before retention; suggesting that DHEAS 
enhanced the storage and/or consolidation of the learned paradigm but not retrieval (125).   
 Other studies have investigated the anti-amnestic properties of DHEA(S) using a 
variety of amnestic agents.  Flood et al. were again the first to show the anti-amnestic 
properties of excitatory neurosteroids using multiple routes of administration (120-122).  
Maurice et al. confirmed the antiamnestic effect of DHEA and DHEAS in mice utilizing 
multiple memory paradigms (Y maze, water maze, passive avoidance) with multiple 
amnestic agents (126-128).  Moreover, Maurice et al. demonstrated that DHEAS had 
effects on learning and/or storing information but no effect on recall of the same 
information (127).   
 DHEA(S) has memory enhancing and anti-amnestic effects on several brain 
locations associated with memory function, suggesting a global effect rather than actions 
limited to particular structures.  Paradigms utilized to show the memory enhancing 
effects of DHEA(S) rely on different neuronal structures, especially the hippocampus, the 
amygdala and frontal cortical regions (for review see 129).   
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 Since DHEA(S) concentrations decrease significantly with age in humans and 
multiple beneficial effects of DHEAS have been documented in rodents, many studies 
have investigated the relationship between DHEA(S) and cognition in humans. High-
functioning elderly patients, as defined by cognitive and functional examinations, possess 
higher DHEAS levels compared to patients in the median or lower functioning groups 
(132, 133). Recent studies have shown that among Alzheimer’s disease patients, those 
with higher concentrations of plasma DHEAS performed better on tests of association, 
digit span, and mini mental status exams when compared to those with lower levels of 
this neurosteroid (137).       
 There are several possible pathways by which neurosteroids enhance memory 
function.  The GABAergic neurons of the nucleus accumbens are known to synapse upon 
cholinergic neurons of the MS which then form the major cholinergic projections to the 
hippocampus (155).  Therefore, DHEA(S) may enhance memory by disinhibiting the 
cholinergic neurons of the MS and increasing concentrations of acetylcholine in the 
hippocampus.  In support of this hypothetical pathway, peripheral administration of 
DHEAS enhanced hippocampal ACh release in vivo, and this enhancement occurred in a 
dose-dependent manner (155).  In further support of this hypothesis, Yoo et al. 
demonstrated a dose dependent increase in hippocampal long term potentiation following 
treatment with DHEAS (156).  Where the cognitive enhancing effects associated with 
DHEAS are due specifically to changes in Ach release in the hippocampus and cortex is 
currently unknown.  One possibility is that DHEAS may also affect non-cholinergic 
systems in ways which can compensate for the loss of muscarinic cholinergic activity.  If 
so, then DHEAS could potentially provide effective agents for the treatment of cognitive 
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dysfunctions associated with a loss of basal forebrain cholinergic neurons such as in AD.  
In this study the approach is to produce selective lesions of the cholinergic neurons 
projecting to the hippocampus using SAP.  We will then assess the ability of DHEAS to 
enhance learning and memory in the DMP task.  This study will reveal whether DHEAS 
can attenuate learning and memory in the DMP T-maze task under conditions when most 
of the cholinergic projections to the hippocampus have been eliminated.  DU-14 is a non-
selective steroid sulfatase inhibitor preventing the metabolism of many different sulfated 
neurosteroids (DHEAS, PS, etc.); therefore results from Experiment B cannot be related 
to the action of a single neurosteroid.  This study differs from Experiment D in that only 
DHEAS will be administered and examined for its ability to attenuate performance of 
SAP-MS treated animals in the DMP task.     
 
2. Methods 
 Immunolesioning of the cholinergic neurons of the MS with SAP was performed 
as documented in Experiment A.  Acclimation and acquisition of the DMP T-maze task 
was performed as documented in Experiment B.  Analysis of the DMP behavior data was 
performed as documented in Experiment D.  Following behavioral testing ChAT activity 
in the hippocampus and frontal cortex was determined for each animal as described in 
Experiment A.  SAP treated animals that did not show selective decrease in ChAT 
activity within the hippocampus were eliminated from the study. 
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i.  Dehydroepiandrosterone sulfate (DHEAS) Treatment: 
 Fourteen days after SAP or aCSF infusion, the animals were randomly separated 
into various DHEAS treatment groups and controls.  Various concentrations of DHEAS 
(0, 3, 10, 20 mg/ml) were dissolved in sterile saline.  DHEAS doses were made fresh 
daily and protected from light.  DHEAS (3, 10, 20 mg/kg), or vehicle (saline) was 
administered, via an IP injection, 30 mins prior to daily training until the animal reached 
a criterion of 15 correct choices out of 16 consecutive trial pairs.  Due to the potential of 
DHEAS to be converted to DHEA and the short half-life of DHEA 30 min prior to testing 
was chosen.  A daily IP injection was utilized to better replicate a potential treatment 
regiment which could be utilized in humans.  Prior studies demonstrated that the same 
concentrations of DHEAS used in the current study were able to significantly increase 
hippocampal Ach release 60 minutes following an i.p. injection (113).  DHEAS also 
reversed scopolamine induced amnesia in a dose-dependent manner (113, 152, 205).  It 
should be noted that the optimal dose of DHEAS for reversing scopolamine amnesia (20 
mg/kg) was much lower than the dose which produced the maximal release of 
acetylcholine from the hippocampus.        
 
 
3. Results 
 
 Of the original 67 animals, five animals failed to reach criterion on the DMP task 
or displayed a side bias and were excluded from the study.  One animal from the 
following groups failed to complete the DMP task: aCSF vehicle, aCSF DHEAS (3 
mg/kg), aCSF DHEAS (10 mg/kg) animals while the other two animals were SAP-MS 
DHEAS (10 mg/kg) treated.  Analysis of the remaining animals indicated that DHEAS 
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treatment failed to improve the days to criterion for either the aCSF or SAP-MS treated 
animals (Fig. 13 & 14).  Table 2 summarizes the effects of DHEAS treatment on days to 
criterion. 
 
Table 2:  Summary of days-to-criterion data following daily DHEAS injections. 
 
Lesioning DHEAS Treatment 
(mg/kg) 
Days to 
Criterion 
S.E.M Number 
aCSF 0 14.00 1.07 9 
aCSF 3 14.88 1.30 8 
aCSF 10 17.00 1.54 8 
aCSF 20 12.67 1.77 9 
SAP-MS 0 17.38 3.34 8 
SAP-MS 3 15.83 4.07 6 
SAP-MS 10 22.00 4.24 7 
SAP-MS 20 16.22 5.95 9 
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Figure 13.  Effects of differing DHEAS treatments on the number of days to reach 
criterion in the DMP T-maze task.  
Bar graph representing the effects of different DHEAS treatments on days to criterion in the DMP 
task for both aCSF control animals (panel A) and SAP-MS animals (panel B).  Top of bar 
represents the mean number of days to reach criterion ± sem.  There was no significant effect of 
DHEAS treatment on days to criterion. 
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Examination of the learning curves (Fig. 14A &14B) show that all animals 
performed at similar, below chance, levels at the start of DMP training.  By day thirty all 
animals had reached criterion.  There were minimal effects on the rate of performance 
with DHEAS treatments for either aCSF or SAP-MS treated animals.  Analysis of the 
learning curves for aCSF rats treated with DHEAS (fig. 14A) by two-way ANOVA 
demonstrated a significant effect of “Block” (p < 0.0001), but no significant effect of 
“Treatment” (p = 0.077) or “Treatment” X “Block” interaction (p = 0.43).  A post-hoc 
test showed no significant difference between aCSF DHEAS treatment groups for any of 
the blocks.   
 Analysis of the learning curves for SAP-MS rats treated with DHEAS (Fig. 14B) 
by two-way ANOVA demonstrated a significant effect of “Block” (p < 0.0001) and 
“Treatment” (p < 0.0001), but no “Treatment” X “Block” interaction (p = 0.41).    A 
separate analysis of performance within a block revealed SAP vehicle treated animals 
performed significantly better than SAP DHEAS (10mg/kg) treated animals during 
blocks 1 through 3 of training. 
 
 
 
 
 
 
102 
 
1 2 3 4 5 6 7 8 9 10
0
25
50
75
100
Vehicle
DHEAS-3
DHEAS-10
DHEAS-20
Block (3 days)
Pe
rc
en
ta
ge
 C
or
re
ct A
 
1 2 3 4 5 6 7 8 9 10
0
25
50
75
100
Vehicle
DHEAS-3
DHEAS-10
DHEAS-20
B
Block (3 days)
Pe
rc
en
ta
ge
 C
or
re
ct
*
*
*
 
 
Figure 14.  Effects of differing DHEAS treatments on the rate of acquisition in the 
DMP T-maze task.  
Learning curve showing effects of DHEAS treatment on the rate of DMP acquisition for 
aCSF (panel A) and SAP-MS (panel B) lesioned rats.  Points represent the mean 
percentage correct for each treatment group during a 3 day period of training.  DHEAS 
had no significant effect on the performance of aCSF animals (panel A).  SAP animals 
treated with DHEAS (10mg/kg) significantly impaired performance during blocks 1-3 
(panel B). * p < 0.01; when comparing DHEAS (10mg/kg) to vehicle treated animals.  
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4.  Discussion 
 
 Examination of learning curves and days to criterion data found that differing 
concentrations of DHEAS treatment had no effect on acquisition of the DMP task for 
either control or SAP lesioned animals.  Specifically, DHEAS treatments did not affect 
the number of days rats required to reach criterion and had no effect on performance 
within any of the training blocks.  These findings did not support the initial hypothesis 
that DHEAS would attenuate the cognitive deficits associated with SAP lesions of the 
MS. 
 Prior studies demonstrated that the same concentrations of DHEAS used in the 
current study were able to significantly increase hippocampal acetylcholine release 60 
minutes following an i.p. injection (113).  DHEAS also reversed scopolamine induced 
amnesia in a dose-dependent manner (113, 152, 205).  It should be noted that the optimal 
dose of DHEAS for reversing scopolamine amnesia (20 mg/kg) was much lower than the 
dose which produced the maximal release of acetylcholine from the hippocampus.  
However, unlike with scopolamine induced amnesia, SAP lesion of the MS permanently 
destroyed the cholinergic afferents to the hippocampus.  The current results suggest that 
the memory enhancing effects of DHEAS are some what dependent on an intact septo-
hippocampal tract.  However, the rats with an intact septo-hippocampal tract were also 
unaffected by DHEAS administration in the DMP task.  This result suggests one of two 
possibilities, a ceiling effect where control animals function at maximum efficiency for 
acquisition of the DMP task, or that the DMP task is not an appropriate test for 
demonstrating the memory enhancing effects of DHEAS.  This second explanation is 
unlikely since Melchior and Ritzmann (124) demonstrated that when administered i.p., 
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both DHEA and DHEAS enhanced short-term working memory as assessed with a T-
maze paradigm.  A prior study (Experiment C) suggests that the utilization of different 
spatial learning strategies in the DMP T-maze task is greatly affected following SAP 
lesioning of the MS.  These results may suggest that DHEAS is unable to change the 
utilization of these learning strategies adopted by these rats during acquistion. Other 
studies using the Morris water maze could better assess the effects of DHEAS on spatial 
working memory.   
 Flood et al. were the first to show the memory-enhancing effects of DHEA and 
DHEAS, in both young (120-122) and old (123) mice using a foot shock paradigm.  In 
their extensive studies, multiple routes of administration (i.c.v., s.c., oral) were utilized, 
all leading to an inverted U-shaped dose response curve for memory-enhancing effects.  
It is possible that the concentrations of DHEAS used in this study are unable to enhance 
memory. In support of this conclusion, there was no significant change in the DMP 
performance for aCSF treated controls.   However, prior studies demonstrated that the 
same concentrations of DHEAS used in the current study were able to significantly 
increase hippocampal Ach release 60 minutes following an i.p. injection (113).  
Furthermore, it has been demonstrated that 20 mg/kg is the optimal dose of DHEAS for 
reversing scopolamine amnesia in the Morris water maze (113, 152, 205).  
 Surprisingly, SAP treated rats failed to show impaired performance in the DMP 
task compared to sham controls.  This result may have been due to enhanced arousal 
associated with the injection procedure for DHEAS and vehicle.  One must consider the 
potential of enhanced arousal with an i.p. drug administration and should alter the 
treatment regiment to minimize this complication.  Administration of DHEAS through an 
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implanted osmotic pump or a few hours before or after training may reveal its potential to 
attenuate learning and memory impairments associated with selective loss of cholinergic 
neurons projecting to the hippocampus. 
     
F.  Effects of aversive stimulus on spatial acquisition of medial septum cholinergic 
lesioned rats. 
 
1. Introduction 
 In experiment A and B we showed that SAP can be used to produce selective 
cholinergic lesions in the MS, resulting in a marked decrease in markers of hippocampal 
cholinergic function, as well as significant impairment in the acquisition of a DMP T-
maze task. Other investigations, though, have reported only limited effects of MS SAP 
lesions in other spatial tasks. For example, Dornan et al. (179) reported that a selective 
reduction of cholinergic transmission in the basal forebrain was by itself insufficient to 
account for the functional impairments in spatial learning of rats using a Morris water 
maze paradigm. Baxter et al. (180, 181), utilizing a Morris water maze task reported 
similar findings.  
 These conflicting results may be the consequence of the environment and stress 
associated with the particular task.  For example, Sandi et al., found that lowering water 
temperature from 25 to 19 degrees Celsius resulted in both increased post training 
corticosterone levels and enhanced acquisition and retention in the Morris water maze 
(206).  Moreover, emotional and stressful experiences, via the activation of specific 
hormonal and brain systems, alter learning and memory processes (159, 160, 212).  
Stress, depending on intensity and duration, can either facilitate or impair cognitive 
functions, particularly spatial learning and memory performance (162).  Short periods of 
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a mild stressor can enhance acquisition of certain spatial learning tasks (36, 163), while 
longer periods of stress have impaired performance in a variety of spatial tasks (165, 
213).  Therefore, we hypothesize that the effects of basal forebrain cholinergic lesions on 
acquisition of a spatial task may have different outcomes as a consequence of the 
differing levels of stress inherent to the tasks.  A number of studies have shown that 
intraperitoneal injection of saline acts as a mild stressor, resulting in modest elevations in 
plasma corticosterone (214, 215).  In the present study, we evaluated whether daily 
introduction of this mild aversive stimulus prior to training would alter the effect of septal 
cholinergic lesions on acquisition of a DMP task.  Specifically, we predicted that 
introduction of the stressor would reduce the impairment produced by septal cholinergic 
lesions, consistent with the relative lack of effect of SAP lesions on acquisition of the 
more stressful Morris water maze task previously described. 
 
2. Methods 
 Selective immunolesioning of the cholinergic neurons of the MS with SAP was 
performed as documented in Experiment A.  Acclimation and acquisition of the DMP T-
maze task was performed as documented in Experiment B.  Analysis of behavior data 
was performed as documented in Experiment D.  Following behavioral testing ChAT 
activity in the hippocampus and frontal cortex was determined for each animal as 
described in Experiment A.  SAP treated animals that did not show selective decrease in 
ChAT activity within the hippocampus were eliminated from the study. 
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i.  Aversive Stimulus: 
 Fourteen days following surgery, animals were randomly separated into aversive 
or non-aversive treatment groups (SAP, 0.22g SAP; aCSF, control aCSF; A, aversive; 
and NA, non-aversive).  The SAP-A and aCSF-A groups 30 min. prior to training, 
received an injection of sterile saline (10ml/kg, IP), while the SAP-NA and aCSF-NA did 
not.   
 
 
3.  Results 
 
 Of the original 32 animals, two animals (1 aCSF-NA, 1 SAP-NA) failed to run the 
maze, reach criterion, or displayed side biases and were excluded from the study.  
Treatment significantly affected the number of days that animals required to reach 
criterion [F(3,26) = 6.95, p = 0.0014] (Fig. 15). Specifically, SAP-NA animals required 
more days to reach criterion than corresponding aCSF-NA controls (21.7 ± 1.6 days 
versus. 15.9±0.5 days, p < 0.05). In contrast, SAP treated animals that also received the 
mild aversive stimulus did not require significantly more days to reach criterion than 
corresponding aCSF-A animals (16.8 ± 1.3 for SAP-A animals versus. 13.4 ± 1.4 days 
for aCSF-A animals, p > 0.05).  Also, SAP-A treated animals took significantly fewer 
days to reach criterion than SAP-NA animals (p < 0.05), however, there was no 
significant difference in days-to-criterion between the aCSF-A and the aCSF-NA treated 
controls (p > 0.05).  Note that by day 20 of training, all control animals had reached 
criterion, 7 of 8 SAP-A animals had reached criterion, and only 3 of 7 SAP-NA animals 
had reached criterion. By day 30 of training, only a single animal in the SAP-A group had 
not reached criterion. 
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Figure 15.  Effects that the introduction of a mild aversive stimulus had on the 
number of days to reach criterion in the DMP T-maze task.  
Bar graph representing the effect of an aversive stimulus on the average number of days required 
to reach criterion for each treatment group.  Top of bar represents the mean number of days to 
reach criterion in the DMP task ± sem.  The SAP-NA group required significantly more days to 
reach criterion than the corresponding aCSF-NA controls.  In contrast, the SAP-A group did not 
require significantly more time to reach criterion than the corresponding aCSF-A controls.  *  p < 
0.05.  
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 Analysis of the learning curves (Fig. 16) by two-way ANOVA demonstrated a 
significant effect of SAP treatment (F[3,156] = 103.0 p < 0.0001), a significant effect of 
‘Block’ (F[5,156] = 11.48, p < 0.0001), and a significant Treatment x Block interaction 
(F[15,156] = 1.811, p = 0.0374) (Fig. 15). A separate analysis of Blocks 3 and 4 revealed 
significant differences between treatment groups (F[3,32] = 3.739, p = 0.021 for Block 3; 
F[3,32] = 8.572, p = 0.0003 for Block 4).  One-way ANOVA analysis within each block 
revealed a significant decrease in performance for SAP-NA compared to aCSF-NA 
treated animals during Blocks 3 and 4. Additionally, the SAP-A group performed 
significantly better than the SAP-NA group (p < 0.05).  Differences between the aCSF-A 
and SAP-A treated groups were not statistically significant during any block.  
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Figure 16:  Effects that the introduction of a mild aversive stimulus had on the rate 
of acquisition in the DMP T-maze task.  
Learning curves showing acquisition of the DMP task across six 5-day blocks of training.  Values 
represent the mean percentage correct choices for each treatment groups during each period of 
training.  Note that all groups showed improved performance over time; however during Blocks 3 
and 4 the performance of the SAP-NA-treated animals was significantly worse than the 
corresponding aCSF-NA-treated controls (* = p <  0.05; ** = p < 0.01).  Also, note that during 
Block 4, the performance of the SAP-A-treated animals was significantly better than the SAP-
NA-treated animals (+ = p < 0.05). Differences in acquisition between the aCSF-Aand SAP-A 
treatment groups were not statistically significant during any period. 
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 Again we observed that during the early stages of training all of the animals 
appeared to adopt a turning strategy.  Again there was no significant difference in the 
amount of time that each group took to adopt the turning strategy.  The number of days 
that animals engaged in a turning strategy was significantly increased following SAP 
lesioning of the medial septum (p < 0.05) (Fig. 17).  SAP treated animals engaged in a 
turning strategy for 13.78 ± 1.84 days while aCSF treated controls only engaged in this 
strategy for 7.75 ± 1.29 days.  Interestingly, following the introduction of an aversive 
stimulus this significant difference was no longer observed (7.89 ± 1.37 for aCSF-A 
treated animals versus 9.75 ± 1.31 for SAP-A treated animals;  p = 0.54).  
 To determine whether the differences seen in days engaged in a turning strategy is 
enough to explain the effects of treatment differences on acquisition of the DMP task, the 
days using the turning strategy were subtracted from days required to reach criterion (Fig. 
17).  Again a one-way ANOVA revealed that once the number of days rats using a 
turning strategy were subtracted from days to criterion, no significant effect on days to 
criterion is seen with SAP lesion of the MS (p = 0.32) (Fig 18).  This indicated that a 
portion of the effect of the aversive stimulus maybe related to the number of days animals 
utilized a turning strategy.   
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Figure 17:  Effects that the introduction of a mild aversive stimulus had on the 
utilization of a persistent turning strategy. 
The number of days rats displayed a turning strategy during DMP T-maze training.  The top of 
the bar represents the mean ± s.e.m.  Note that SAP-NA treated animals adopted a turning 
strategy for more days compared to controls.  Also note that there was no significant difference 
between aCSF-A and SAP-A.  *p < 0.05 relative to the aCSF-NA treated controls. 
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Figure 18:  Effect that the introduction of a mild aversive stimulus had on the 
number of days to reach criterion, excluding the days utilizing a turning strategy.  
Days to criterion minus day animals are engaged in a turning strategy.  SAP-NA treated animals 
did not differ significantly in the number of days to reach criterion when compared to controls 
(p=0.54). 
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4.  Discussion 
 As stated above, the data show that SAP-lesions significantly impaired acquisition 
of the DMP task relative to controls.  As predicted, this effect was significantly reduced 
by application of a mild aversive stimulus each day prior to training (Fig. 14, 15).  This 
finding demonstrated that a mild aversive stimulus could attenuate or mask a deficit 
resulting from lesion of MS cholinergic neurons on acquisition of a spatial task.  This 
result is consistent with studies of working memory that used paradigms with an aversive 
component and found that selective cholinergic lesions of the MS did not produce 
acquisition deficits in spatial working memory (179-181).  Notably, application of the 
aversive stimulus had no significant effect on DMP acquisition in the non-lesioned 
control animals.  This suggests that the aversive stimulus may only affect performance in 
the presence of the lesion; however, the possibility of a ceiling effect on performance in 
the non-lesioned animals cannot be excluded.    
 One might expect an aversive stimulus to have the greatest effect early during 
training, when the stimulus is relatively novel, and a lesser effect as the animal becomes 
habituated to the stimulus later in training.  The effect of the aversive stimulus in the 
SAP-arousal group, though, became apparent relatively late in training (days 16–20; 
block 4). It is possible that the effect of the aversive stimulus in SAP lesioned animals 
was the result of the strategy shift that occurred relatively late during acquisition of the 
task.  This may suggest that SAP lesioned rats have diminished ability to habituate to 
the low level of stree experienced with the i.p. injection.  The effect of the i.p. injection 
may also affect the level of reliance on a single learning strategy for SAP treated animals 
early in training, which is manifested as diminished rate acquisition later in training.  The 
115 
 
SAP treated animals may be more reliant on the turning strategy early in training, 
decreasing the potential to adopt the more successful strategy.  Notably, there was no 
significant difference in hippocampal ChAT activity between the SAP-A and the SAP-
NA treated groups, suggesting that the differences in T-maze acquisition between the two 
groups was not due to a bias resulting from a greater loss of septo-hippocampal 
cholinergic projections in one group compared to the other. 
 The sensitivity of any task to lesions of a single pathway depends on whether the 
lesion involves the principal pathway activated during the task, as opposed to several 
pathways that are activated. The hippocampus receives inputs from a variety of cortical 
and subcortical structures, including the entorhinal cortex, amygdala, medial septum, 
thalamus, and monoaminergic cell groups in the midbrain and hindbrain. Mild stress has 
been shown to enhance acquisition of certain spatial learning tasks via hippocampal 
activation utilizing neuronal pathways that do not involve the MS (164, 217).  Therefore, 
a task with a mildly aversive component may possibly preserve acquisition of a spatial 
navigation task in animals with a septal-hippocampal cholinergic lesion via pathways that 
are independent of the septal-hippocampal tract. The result would be a loss of sensitivity 
with tests for impairments in learning/memory resulting from a septal-hippocampal lesion 
that involved a mildly aversive stimulus, e.g. the MWM. 
 One must consider the possibility that there are no purely hippocampal tasks. 
Most spatial tasks can be solved using a variety of strategies (198), each of which may 
rely to varying degrees on different neural substrates.  As an example, during stress, it is 
well established that epinephrine released from the adrenal cortex can activate adrenergic 
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receptors that facilitate memory function (167-169).  Adrenergic receptors found on vagal 
afferents that project to the nucleus of the solitary tract can subsequently activate neurons 
that project to the amygdala (174), a structure long associated with the acquisition of 
memories of aversive stimuli (170, 172-174, 213) and the modulation of memory 
processes involving the hippocampus (175-177). Consequently, it is possible that in 
addition to enhancing the activity of non-cholinergic inputs to the hippocampus, 
administration of a mild aversive stimulus could also activate parallel memory systems 
(219, 220) that enhance performance, perhaps by strengthening the use of strategies less 
dependent on hippocampal cholinergic inputs.  Evidence in support of this theory is that 
following the introduction of an aversive stimulus, SAP-lesioned rats no longer utilized 
the persistent turning strategy for a greater number of days than control animals.  This 
result is consistent with, and may help to explain, the reported discrepancies between the 
effects of septal cholinergic lesions on acquisition of MWM versus land-based (e.g., T-
maze) tasks. While both types of tasks can be used to evaluate spatial learning and 
memory, the levels of stress are higher in a water maze task due to the aversive 
environment of the pool (221, 222).  Therefore, performance of the DMP T-maze task 
may be more sensitive to SAP-lesion because it is less aversive. This is consistent with 
the current study that showed administration of a mild stressor eliminated the sensitivity 
of the DMP task to the cholinergic lesion; thereby, producing results more like those 
reported with the MWM. 
 There is a report in which SAP lesion induced a deficit in MWM performance 
(223).  However, the methodology utilized intraventricular injection of SAP, resulting not 
only in a broader cholinergic lesion of brain structures than intra-parenchymal injection 
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in the MS, but also the loss of purkinje cells of the cerebellum (224). Other studies, after 
injecting SAP into the MS and NBM, failed to detect a deficit in performance in the 
radial arm maze, a non-aversive task (225).  However, this result may have been a 
consequence of the particular environment in which the animals were tested or specific 
aspects of the testing paradigm. 
 In summary, the findings demonstrate that cholinergic inputs to the hippocampus 
play a role in the acquisition of the DMP task under low-stress conditions, but that the 
impact of the cholinergic lesion is attenuated in the presence of a mild aversive stimulus. 
In addition, the data suggest caution when interpreting negative findings based on a 
single behavioral task, or a set of tasks that emulate a single environmental condition. 
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IV. CONCLUSIONS 
 The results of these investigations are significant to the ongoing efforts to develop 
models that mimic memory deficits associated with many forms of dementia as well as 
developing treatments for these diseases.  With Alzheimer’s disease, the cholinergic 
neurons of the basal forebrain are one of the most sensitive targets of the degenerative 
processes.  The results demonstrated that low doses of SAP selectively destroyed 
cholinergic neurons of the MS in rats; resulting in impaired rate of acquisition of a DMP 
T-maze task.  This provides evidence that SAP-MS lesioned rodents tested in the DMP 
task can be utilized as a model for cholinergic deterioration seen with aging and certain 
forms of dementia.  Furthermore this model can be used to develop and test new 
medications which could possibly attenuate the cognitive defects in the DMP task related 
with diminished cholinergic innervations of the hippocampus.  Microdialysis studies 
using SAP lesioned animals could also explore treatment regiments which are able to 
increase the cholinergic tone of the hippocampus.  Medications which are able to improve 
learning and memory in SAP lesioned animals may also possibly provide a new treatment 
for dementia that does not rely on cholinergic actions.  
The results also showed that rats during different periods of training in the DMP 
task adopted different navigation strategies.  During the early stages of training the rats 
used an egocentric (response) strategy manifested as persistent turning; and later 
switched to an allocentric strategy using extra-maze cues to select the correct goal arm.  
The diminished rate of acquisition associated with the SAP lesion of the MS was the 
result of the delayed adoption of an allocentric strategy used to reach criterion.  These 
results add to the growing literature that describes how animals solve different learning 
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and memory tasks. These results also provide much insight into the function of different 
neuronal systems during distinct stages of the learning and memory process.  In the 
future, when testing treatments that attenuate the diminished rate of acquisition associated 
with SAP-MS lesions one could assess the ability of the treatment to alter the utilization 
of the different learning strategies.  To further clarify the neuronal systems involved in 
the different learning strategies it is vital to develop a microdialysis experiment where 
changes in the concentrations of different neurotransmitters during the different stages of 
learning in the DMP task could be determined.  It would also be informative to use 
selective neurotoxins to lesion different neuronal systems and determine how these 
lesions effect the utilization of learning strategies used in spatial learning and memory 
tasks.   
 DHEA and its sulfated ester DHEAS have gained significant interest in the field 
of neuroscience and DHEA is sold as a herbal remedy for cognitive decline.  The exact 
mechanisms by which DHEAS and steroid sulfatase inhibitors enhance cognition remain 
unclear.  Moreover, the long term safety of these treatments is currently unknown.  The 
results demonstrated that treatments with steroid sulfatase inhibitor, DU-14, further 
impaired the rate of acquisition of the DMP T-maze task in SAP treated rats. Treatments 
with differing concentrations of DHEAS were unable to attenuate the impaired rate of 
acquisition of the DMP T-maze task associated with SAP lesion of the MS.  Furthermore, 
both treatments were unable to improve cognition in the control animals.  These results 
suggest that the memory enhancing effects associated with DU-14 and DHEAS 
treatments could possible require intact cholinergic afferents to the hippocampus.  This 
may provide a potential mechanism for the memory enhancing and anti-amnestic effects 
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observed with DHEAS and DU-14 treatments.  Before DU-14 can be exclude as a 
possible treatment for cognitive decline associated with SAP-MS lesions, future studies 
utilizing different concentrations and multiple learning and memory paradigms need to be 
performed.  Future experiments testing the cognitive enhancing effects of DHEAS should 
administer the drug through an implanted continue release osmotic pump or at a time 
which will not interfere with the behavioral testing.  In this study and others, DHEAS has 
been administered as an i.p. injection.  When this route of administration is utilized one 
could not exclude possible peripheral effects.  To determine the central effects of DHEAS 
a study needs to be designed investigating the effects of direct administration of the 
neurosteriod into the CNS on learning and memory.  To better elucidate the mechanism 
by which DU-14 enhance memory, microdialysis experiments need to be designed that 
can determine if DU-14 or DHEAS can increase the cholinergic tone of the hippocampus 
and alter the release of other neurotransmitters in control and SAP-MS treated animals.  
This could further demonstrate that an intact cholinergic afferent to the hippocampus is 
need for DU-14 to exhibit its memory enhance and anti-amnestic effects.  Since the 
mechanism by which DHEAS is produced in the brain or enters the CNS is unclear, 
future studies need to elucidate the mechanism by which DHEAS is produced in the CNS 
or crosses the BBB.  Once these mechanisms are determined new drugs could be 
developed to target the mechanisms and increase DHEAS levels in the aging and those 
patients with dementia. 
Interestingly, the introduction of a mild aversive stimulus was able to improve 
acquisition of the DMP task in SAP-lesion rats and decrease the use of a persistent 
turning strategy.  These findings suggest that the activation of functionally parallel 
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neuronal systems, reduce the influence the hippocampal cholinergic afferents have on the 
cognitive processes used to acquire the DMP task. When performing behavioral testing 
one need to take into consideration environmental factors which may enhance the stress 
and arousal levels of the animals.                  
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